<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Systemic treatment for advanced hepatocellular carcinoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Systemic treatment for advanced hepatocellular carcinoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Systemic treatment for advanced hepatocellular carcinoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keith E Stuart, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 30, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H635218888"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hepatocellular carcinoma (HCC) is an aggressive tumor that usually occurs in the setting of chronic liver disease and cirrhosis. It is typically diagnosed late in the course of the chronic liver disease [<a href="#rid1">1</a>]. The patient's hepatic reserve, as indicated by the Child-Pugh classification, often dictates therapeutic options  (<a class="graphic graphic_table graphicRef78401" href="/d/graphic/78401.html" rel="external">table 1</a>).</p><p>This topic will discuss systemic treatment approaches for patients with advanced unresectable HCC for whom liver transplantation, and liver-directed therapy are not appropriate. An overview of treatment for HCC, surgical treatment, liver-directed nonsurgical therapies, and the clinical manifestations and diagnosis of HCC are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2489.html" rel="external">"Overview of treatment approaches for hepatocellular carcinoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2488.html" rel="external">"Surgical resection of hepatocellular carcinoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2490.html" rel="external">"Liver transplantation for hepatocellular carcinoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2487.html" rel="external">"Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates who are eligible for local ablation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15589.html" rel="external">"Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates not eligible for local thermal ablation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma"</a>.)</p><p></p><p class="headingAnchor" id="H859162512"><span class="h1">EVOLUTION OF SYSTEMIC THERAPY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Historical context</strong> – Previously, palliative systemic therapy with conventional cytotoxic chemotherapy agents had not been used routinely for patients with advanced HCC for a number of reasons:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>HCC is considered a relatively chemotherapy-refractory tumor, in part due to the high rate of expression of drug resistance genes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Systemic chemotherapy is usually not well tolerated by patients with significant underlying hepatic dysfunction.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chemotherapy may also be less effective overall in patients with significant cirrhosis. This was illustrated in an evaluation of predictive factors among 147 patients receiving chemotherapy for HCC [<a href="#rid2">2</a>]. There were no objective responses among patients with a poor performance status, ascites, portal vein tumor thrombus, or serum bilirubin &gt;2 mg/dL [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The role of cytotoxic chemotherapy, which has modest efficacy for HCC, at best, has diminished with the advent of newer immunotherapy and molecularly targeted therapy approaches, which demonstrated better efficacy and tolerability. Cytotoxic chemotherapy has been removed from guidelines for advanced HCC by both the NCCN and ESMO [<a href="#rid3">3,4</a>]. However, at some institutions, chemotherapy is still offered to select patients for third- or fourth-line therapy if not deemed optimal candidates for other approved therapies. (See <a class="local">'Systemic chemotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advances of targeted therapies and immunotherapy</strong> – Since 2008, there has been a resurgence of interest and enthusiasm for systemic therapy of HCC with the emergence of data showing that:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The molecularly targeted agents <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> and <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a> improve survival over best supportive care alone.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">Atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> and <a class="drug drug_general" data-topicid="139983" href="/d/drug information/139983.html" rel="external">tremelimumab</a> plus <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a> improve survival over first-line <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>. Given their more favorable toxicity profile [<a href="#rid5">5</a>], and greater efficacy, immunotherapy-based combinations have now become preferred first-line therapy options over sorafenib or other molecularly targeted agents. (See <a class="local">'Choice of therapy'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">Lenvatinib</a> has been shown to be noninferior to first-line <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An overall survival (OS) benefit has been shown in the second-line setting for immune checkpoint inhibitors <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, after progression on <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uncertainties</strong> – These results and US Food and Drug Administration approvals for many of these treatments have radically changed the treatment landscape for advanced HCC. However, the rapid evolution of immunotherapy and molecularly targeted therapy for advanced HCC has also led to several areas of ongoing uncertainty [<a href="#rid6">6</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All of these targeted agents are expensive, and in almost all cases, the demonstration of benefit has been limited to those with well-preserved liver function (ie, no worse than Child-Pugh class A cirrhosis  (<a class="graphic graphic_table graphicRef78401" href="/d/graphic/78401.html" rel="external">table 1</a>)). There still may be a role for cytotoxic chemotherapy in selected medically appropriate patients who cannot obtain these drugs and who have retained adequate hepatic function and a reasonable remaining life expectancy. (See <a class="local">'Systemic chemotherapy'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who have access to all agents, and sufficiently preserved liver function, the best way to sequence the available systemic treatment options for advanced HCC has not been established.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>As discussed in more detail below, the best way to integrate these new systemic therapies into the treatment algorithm for HCC is in flux, particularly for patients with unresectable yet liver isolated HCC not amenable to transplantation or ablation.</p><p></p><p class="headingAnchor" id="H3094964401"><span class="h1">PLACING SYSTEMIC THERAPIES IN THE CONTEXT OF HCC MANAGEMENT</span></p><p class="headingAnchor" id="H2160810254"><span class="h2">Treatment algorithms</span><span class="headingEndMark"> — </span>Treatment options for HCC are divided into surgical therapies (ie, resection, and liver transplantation) and nonsurgical therapies, which may be liver directed (ie, radiofrequency/microwave ablation, arterially directed therapies, external beam radiation therapy) or systemic (predominantly immunotherapy with immune checkpoint inhibitors and molecularly targeted therapies). Treatments are generally selected based upon disease extent and underlying liver function  (<a class="graphic graphic_algorithm graphicRef57014" href="/d/graphic/57014.html" rel="external">algorithm 1</a>). An alternative treatment algorithm is available from the Barcelona Clinic  (<a class="graphic graphic_figure graphicRef139139" href="/d/graphic/139139.html" rel="external">figure 1</a>).</p><p></p><p>Algorithmic approaches such as these can help to conceptualize the available treatment options for HCC, but they may not be applicable in all settings. Furthermore, attempts to generate algorithmic approaches to the treatment of HCC are difficult since new treatments (especially systemic therapies) and indications for various treatments are evolving rapidly, and few studies have addressed the sequencing of active regimens, or the integration of modern systemic therapy into local liver-directed therapies.</p><p>This is particularly relevant for patients with liver-limited disease who are not surgical candidates because of large tumor size, number of lesions, or technically inoperable disease, and do not meet extended transplant criteria. In this setting, locoregional liver-directed therapies have been the de facto mainstay of treatment because of high local response rates and favorable safety profile, especially in the context of minimally effective systemic therapies. However, some of these patients will never receive systemic therapy because of disease progression or treatment-related decline in hepatic function. (See  <a class="medical medical_review" href="/d/html/15589.html" rel="external">"Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates not eligible for local thermal ablation"</a>.)</p><p class="bulletIndent1">Now that more effective systemic therapies have emerged that have been shown to prolong survival, how these therapies should be integrated into the treatment algorithm for such patients is in flux. A major question is should patients be deemed refractory to locoregional therapy before switching to systemic therapy? Would earlier use of systemic therapy or combination strategies (eg, immunotherapy or molecularly targeted therapy plus locoregional therapy) improve outcomes over either systemic therapy or locoregional therapy alone? Emerging data suggest that there are at least two patient populations, those with extensive vascular invasion, and a high intrahepatic tumor burden, who have a poor outcomes with locoregional therapies, and may be better candidates for upfront systemic therapy. Furthermore, data from the LAUNCH trial suggest the potential for better outcomes for transarterial chemoembolization plus <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> versus lenvatinib alone in individuals with a high tumor burden and/or macrovascular invasion [<a href="#rid7">7</a>]. These data are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2489.html" rel="external">"Overview of treatment approaches for hepatocellular carcinoma", section on 'Large intrahepatic tumor burden'</a> and  <a class="medical medical_review" href="/d/html/2489.html" rel="external">"Overview of treatment approaches for hepatocellular carcinoma", section on 'Patients with portal vein tumor thrombus'</a>.)</p><p></p><p>The limitations of treatment algorithms for HCC and a general approach to treatment of HCC are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2489.html" rel="external">"Overview of treatment approaches for hepatocellular carcinoma", section on 'Treatment algorithms'</a>.)</p><p class="headingAnchor" id="H2999525497"><span class="h2">Indications for systemic therapy</span><span class="headingEndMark"> — </span>Systemic therapy is an appropriate option for patients with advanced unresectable HCC who are not amenable to curative or locoregional therapy and have adequate performance status and underlying liver function. Clinical trials are preferred whenever available.</p><p>Candidates for systemic therapy include those with extrahepatic spread, or tumor confined to the liver who progressed after locoregional therapies, or who have extensive vascular invasion  (<a class="graphic graphic_figure graphicRef138754" href="/d/graphic/138754.html" rel="external">figure 2</a>) or a large intrahepatic tumor burden (diffuse and/or bilateral lobar involvement) unsuitable for locoregional approaches  (<a class="graphic graphic_algorithm graphicRef57014" href="/d/graphic/57014.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/2489.html" rel="external">"Overview of treatment approaches for hepatocellular carcinoma", section on 'Large intrahepatic tumor burden'</a> and  <a class="medical medical_review" href="/d/html/2489.html" rel="external">"Overview of treatment approaches for hepatocellular carcinoma", section on 'Patients with portal vein tumor thrombus'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GENERAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H3"><span class="h2">Estimate life expectancy and assess liver function</span><span class="headingEndMark"> — </span>Among patients with HCC, survival is often determined not by tumor aggressiveness or the impact of a systemic treatment, but by the degree of hepatic dysfunction. Several staging or prognostic scoring systems have been developed to guide the prognosis and treatment of patients with HCC. Historically, the Child-Pugh classification  (<a class="graphic graphic_table graphicRef78401" href="/d/graphic/78401.html" rel="external">table 1</a>) was the most commonly used in clinical studies to define a population with relatively well preserved liver function, although it was neither developed nor validated in patients with HCC [<a href="#rid8">8</a>]. Despite this, we still endorse the use of the Child-Pugh classification for assigning the degree of hepatic dysfunction for the purpose of treatment selection, as it is easy to understand and corresponds to the selection factors used in most clinical studies to date.</p><p>Other prognostic scoring systems include the American Joint Committee on Cancer; tumor, node, metastasis (TNM); Okuda; Cancer of the Liver Italian Program; Chinese University Prognostic Index; Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire; BCLC; Hong Kong Liver Cancer systems; and most recently, the albumin-bilirubin (ALBI) score. These systems were developed based on both surgical and nonsurgical patients with HCC, and they generally aim to classify patients with HCC broadly into those with early-, intermediate-, and advanced-stage disease. One of the most promising is the ALBI score. (See  <a class="medical medical_review" href="/d/html/2476.html" rel="external">"Staging and prognostic factors in hepatocellular carcinoma", section on 'Staging and prognostic scoring systems'</a>.)</p><p>Patients with advanced HCC are a heterogeneous group. There are substantial differences in overall survival (OS) that are due to factors not captured within the subgroups identified by these staging systems, and it is not clear that any of these staging systems provides a more meaningful prognostic discrimination among those with advanced disease compared with others [<a href="#rid9">9,10</a>].However, there is some evidence that outcomes of nonsurgical treatment for HCC might be better predicted by one of these prognostic scoring systems [<a href="#rid11">11,12</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>A prognostic scoring system for patients with advanced HCC not amenable to locoregional therapy has been proposed (the Advanced Liver Cancer Prognostic System [ALCPS]) that allows the separation of three prognostic groups with significantly different three-month survival [<a href="#rid11">11</a>]. The stratification is based on the assignment of a weighted point value to 11 different patient and tumor characteristics, with the total number of points corresponding to an estimated likelihood of three-month survival  (<a class="graphic graphic_table graphicRef57772" href="/d/graphic/57772.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A new model has been developed based on serum albumin and bilirubin alone (the ALBI score) that provides a simple, objective, and discriminatory method of assessing liver function in patients with HCC; it was validated in geographically distinct cohorts of patients undergoing surgery for localized disease and <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> for advanced disease [<a href="#rid13">13</a>]. It seems to provide better prognostic discrimination for patients with HCC than the Child-Pugh score; among patients with Child-Pugh class A cirrhosis (who constituted the vast majority of the studied populations), two prognostically distinct subgroups emerged. The objective nature and simplicity of ALBI may diminish interobserver variation (as occurs with the grading of ascites and encephalopathy in the Child-Pugh scoring system) and help to refine prognostic estimates in patients treated for HCC, particularly among those with better liver function. Independent validation of the model is needed. A calculator is available for the ALBI score (<a class="calc calc_professional" href="/d/html/100996.html" rel="external">calculator 1</a>). (See  <a class="medical medical_review" href="/d/html/2476.html" rel="external">"Staging and prognostic factors in hepatocellular carcinoma", section on 'Albumin-bilirubin (ALBI) score'</a>.)</p><p></p><p>While prognostic scoring systems such as these can objectively help clinicians select appropriate candidates for treatment and participation in clinical trials of new agents, there are no prospective data addressing their ability to predict which patients might benefit from any form of therapy. The updated guidelines from BCLC suggest that, for the purpose of treatment selection underlying liver function be evaluated by more than just the conventional Child-Pugh classification [<a href="#rid14">14</a>], but beyond jaundice, refractory ascites, and encephalopathy (which reflect non-preserved liver function); they are vague as to how best to categorize a patient as having "preserved liver function."</p><p class="headingAnchor" id="H2197269706"><span class="h2">Screen for viral hepatitis</span><span class="headingEndMark"> — </span>Many patients with HCC have underlying liver disease, especially infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), and they may be at risk for viral reactivation during active systemic therapy, including immune checkpoint inhibitor immunotherapy [<a href="#rid15">15</a>]. We agree with an updated year 2020 provisional clinical opinion from the American Society of Clinical Oncology, which endorses universal HBV screening for all patients beginning systemic anticancer therapy (cytotoxic chemotherapy, immunotherapy, molecularly targeted therapy) using three tests, hepatitis B surface antigen (HbSAg), hepatitis B core antibody (anti-HBc), total immunoglobulin (Ig) or IgG, and antibody to hepatitis B surface antigen (anti-HBs) [<a href="#rid16">16</a>]. The finding of chronic HBV (HbSAg-positive) or past HBV (HbSAg-negative and anti-HBc-positive) infection requires HBV reactivation risk assessment to determine the need for antiviral prophylaxis. Their recommended approach to HBV screening, monitoring, and antiviral prophylaxis is outlined in the algorithm  (<a class="graphic graphic_algorithm graphicRef129226" href="/d/graphic/129226.html" rel="external">algorithm 2</a>), and discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p>In addition, clinicians should also consider testing for chronic HCV infection prior to initiating potentially immunosuppressive chemotherapy, although the data are less compelling than for HBV testing. Patients with chronic HCV infection who are receiving chemotherapy should undergo serial monitoring of liver function tests, and if there is no dramatic change, continued chemotherapy treatment without dose modification is appropriate. (See  <a class="medical medical_review" href="/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection"</a>.)</p><p class="headingAnchor" id="H225656329"><span class="h2">Predictive markers of response</span><span class="headingEndMark"> — </span>There are few clinically applicable markers to predict disease response to any form of systemic therapy for advanced HCC, with the exception of <a class="drug drug_general" data-topicid="94963" href="/d/drug information/94963.html" rel="external">ramucirumab</a>, which appears to be beneficial for patients with high initial alpha-fetoprotein (AFP) levels. (See <a class="local">'Ramucirumab'</a> below.)</p><p>However, data are evolving:</p><p class="bulletIndent1"><span class="glyph">●</span>As described in detail below, treatment benefit from first-line <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> appears to be higher in patients with hepatitis C viral (HCV) infection than in those with other underlying risk factors for HCC. However, whether patients with other etiologies of chronic liver disease should be offered a first-line treatment other than sorafenib (eg, <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> or combined <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>) is unclear; there are no prospective studies that have examined treatment response to any other form of molecularly targeted therapy based upon etiology of underlying liver disease. (See <a class="local">'Benefit based on etiology of liver disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Emerging data suggest that immunotherapy approaches (eg, front-line <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, or second-line <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> or <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>/<a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>) might be less effective for HCCs that arise in the setting of nonalcoholic steatohepatitis (NASH) as compared with other etiologies [<a href="#rid17">17</a>]. A meta-analysis included 1656 patients treated with front-line atezolizumab plus bevacizumab in the IMBrave 150 trial, or front-line nivolumab in the Checkmate-459 trial, or second-line pembrolizumab in the KEYNOTE-240 trial. (See <a class="local">'Atezolizumab plus bevacizumab'</a> below and <a class="local">'Nivolumab and pembrolizumab'</a> below and <a class="local">'Pembrolizumab'</a> below.)</p><p></p><p class="bulletIndent1">When the data from these three trials were stratified according to underlying etiology of chronic liver disease, the survival benefit of immunotherapy was limited to those with underlying viral liver disease (HR 0.64, 95% CI 0.48-0.84) but not nonviral liver disease (HR 0.92, 95% 0.77-1.11). In two validation cohorts of patients with advanced HCC treated with immunotherapy targeting the programmed cell death 1 receptor pathway, those with nonalcoholic fatty liver disease (NASH, which constituted a small minority of treated patients) had a median survival that was significantly worse than that of patients with other underlying etiologies (5.4 versus 11 months in one cohort, and 8.8 versus 17.7 months in the second cohort). The authors postulated, based on preclinical studies, that the lower responsiveness to immunotherapy in patients with NASH was possibly attributed to NASH-related aberrant T-cell activation causing tissue damage leading to impaired immune surveillance.</p><p></p><p class="bulletIndent1">While intriguing, these results should be viewed as hypothesis-generating only. Validation in prospective trials stratifying outcomes of various immunotherapy treatments according to etiology of chronic liver disease is needed.</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Response assessment</span><span class="headingEndMark"> — </span>For patients receiving systemic therapy for advanced HCC, reimaging is typically carried out using cross-sectional imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) after the initial six to eight weeks of therapy and then every two to three months thereafter. We use modified RECIST for HCC  (<a class="graphic graphic_table graphicRef58792" href="/d/graphic/58792.html" rel="external">table 3</a>) rather than standard RECIST criteria for solid tumors to assess treatment effect. Clinical status and serial measurements of the tumor marker AFP (if initially elevated) should also be considered in addition to imaging when contemplating treatment changes. (See  <a class="medical medical_review" href="/d/html/83809.html" rel="external">"Assessment of tumor response in patients receiving systemic and nonsurgical locoregional treatment of hepatocellular cancer", section on 'Criteria for response assessment'</a> and  <a class="medical medical_review" href="/d/html/83809.html" rel="external">"Assessment of tumor response in patients receiving systemic and nonsurgical locoregional treatment of hepatocellular cancer", section on 'AFP'</a>.)</p><p>Conventionally, treatment response of HCC to systemic therapy has been assessed by radiologic imaging using conventional response criteria, such as the Response Evaluation Criteria in Solid Tumors (RECIST)  (<a class="graphic graphic_table graphicRef74693" href="/d/graphic/74693.html" rel="external">table 4</a>). However, criteria such as these may not accurately reflect response to treatment or tumor viability, particularly in the era of targeted therapy with agents such as <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, which are cytostatic rather than cytotoxic. Early assessment of response to molecularly targeted agents such as these can be challenging since tumor necrosis, extension, and radiologic appearance can be inhomogeneous. As an example, the predominant patterns of HCC response after sorafenib on dynamic contrast-enhanced MRI are T1 hyperintensity due to coagulation, T2 tumor hyperintensity due to edema, and diminished enhancement in the arterial phase due to necrosis. On CT, sorafenib decreases HCC enhancement without necessarily affecting tumor size. As with locoregional therapies, residual thick and nodular foci of arterial enhancement within HCC suggest residual viable tumor.</p><p>Furthermore, an increase in tumor size due to necrosis has been reported in patients treated with multikinase inhibitors, such as <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, a phenomenon referred to as "pseudoprogression" [<a href="#rid18">18</a>].</p><p>An HCC expert consensus proposed the use of modified RECIST, which mainly measures tumor viability, in assessing response for patients with HCC treated with targeted agents, such as <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>  (<a class="graphic graphic_table graphicRef58792" href="/d/graphic/58792.html" rel="external">table 3</a>) [<a href="#rid19">19-21</a>]. (See  <a class="medical medical_review" href="/d/html/83809.html" rel="external">"Assessment of tumor response in patients receiving systemic and nonsurgical locoregional treatment of hepatocellular cancer", section on 'Measuring tumor dimensions versus tumor viability'</a>.)</p><p class="headingAnchor" id="H1537083667"><span class="h3">Immunotherapy</span><span class="headingEndMark"> — </span>The patterns of response to treatment with immunotherapy (eg, immune checkpoint inhibitors) differ from those with molecularly targeted agents or cytotoxic chemotherapy. (See <a class="local">'Checkpoint inhibitor immunotherapy'</a> below.)</p><p>As an example, in early trials of immune-based therapeutics in melanoma, a unique response pattern was seen, termed "pseudoprogression," in which lesions appeared to be larger or new lesions were seen related to changes in imaging characteristics rather than tumor growth. This is particularly common in liver lesions. Even new small intrahepatic lesions of 1 to 2 cm in size could reflect pseudoprogression of prior subcentimeter lesions. Infiltration of lymphocytes and inflammatory changes related to immune activation that eventually leads to a tumor response can make radiographic assessment challenging early in the course of treatment. Transient rises in AFP can also be misleading in this setting [<a href="#rid22">22</a>]. In addition, responses can take appreciably longer to become apparent compared with cytotoxic therapy. As a result of all of these issues, we continue therapy as long as there are no additional signs of progressive disease, such as deterioration in performance status or identification of new distant metastases. (See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Assessing treatment response'</a>.)</p><p>Immune-related response criteria have been proposed to properly recognize the nontraditional patterns of response occasionally seen with checkpoint inhibitors and some other immunotherapies. This subject is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'Immunotherapy response criteria'</a>.)</p><p class="headingAnchor" id="H171845270"><span class="h1">FIT PATIENTS WITH PRESERVED LIVER FUNCTION AND FUNCTIONAL STATUS</span></p><p class="headingAnchor" id="H3454648557"><span class="h2">First-line therapy</span><span class="headingEndMark"> — </span>Systemic therapy is appropriate for patients with advanced unresectable HCC who are unsuitable for locoregional therapy and whose liver function is adequate to tolerate therapy (ie, Child-Pugh class A or B cirrhosis  (<a class="graphic graphic_table graphicRef78401" href="/d/graphic/78401.html" rel="external">table 1</a>)).</p><p class="headingAnchor" id="H2454587171"><span class="h3">Choice of therapy</span><span class="headingEndMark"> — </span>The following represents our recommended approach to first-line therapy:</p><p class="bulletIndent1"><span class="glyph">●</span>Our preferred approach is participation in an ongoing clinical trial testing new therapeutic strategies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a clinical trial is not available or trial participation is not feasible, for healthy patients with an Eastern Cooperative Oncology Group performance status of 0 or 1  (<a class="graphic graphic_table graphicRef72901" href="/d/graphic/72901.html" rel="external">table 5</a>), no worse than Child-Pugh class A cirrhosis, have not recurred following liver transplantation, are not receiving therapeutic anticoagulation, and following management of esophageal varices, if applicable, we suggest <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> rather than other systemic agents.</p><p></p><p class="bulletIndent1">For patients who are unable to receive <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="139983" href="/d/drug information/139983.html" rel="external">tremelimumab</a> plus <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a> is an alternative to <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus bevacizumab. Immunotherapy approaches should be avoided in patients who recur following transplantation because of the high rate of allograft rejection.</p><p></p><p class="bulletIndent1">For less fit patients who have a recurrence following liver transplantation or another contraindication to <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, we suggest monotherapy with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> or <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> rather than conventional cytotoxic chemotherapy. Both are US Food and Drug Administration (FDA)-approved for first-line therapy, and it is not clear that either drug is superior to the other. Where available, donafenib or <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a> are alternatives to sorafenib or lenvatinib.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If monotherapy with a molecularly targeted agent is chosen for initial therapy, American Society of Clinical Oncology (ASCO) guidelines suggest that the choice of treatment with <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> or <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> should be made through a discussion with the clinician and patient, and should include factors such as medical history, severity of liver disease, viral etiology of liver disease, treatment-related toxicity and cost, goals of treatment, and patient preference [<a href="#rid23">23</a>]. However:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some clinicians, including the author, prefer <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> rather than <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> for most patients because of the better tolerability (especially for hand-foot skin reaction, alopecia, fatigue, and anorexia), and the higher objective response rates (ORRs) and longer time to tumor progression (TTP) in the REFLECT trial. (See <a class="local">'Lenvatinib'</a> below.)</p><p></p><p class="bulletIndent2">Other clinicians prefer <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, given the longer duration of experience with this drug than with <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>, the lack of a survival benefit for lenvatinib over sorafenib in the REFLECT trial, and the approval of two second-line regimens (<a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a> and <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>) after failure of first-line sorafenib. There are no data and no approved drugs for treatment of advanced HCC after failure of first-line lenvatinib. (See <a class="local">'Sorafenib'</a> below and <a class="local">'Regorafenib'</a> below and <a class="local">'Checkpoint inhibitor immunotherapy'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment with tyrosine kinase inhibitors (TKIs) may be less effective in patients with more advanced liver disease. Consensus-based National Comprehensive Cancer Network (NCCN) guidelines suggest that <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> use in those with Child-Pugh class B disease be limited to those whose score is no higher than 7  (<a class="graphic graphic_table graphicRef78401" href="/d/graphic/78401.html" rel="external">table 1</a>). NCCN guidelines suggest limiting use of <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> to individuals with no worse than Child-Pugh class A cirrhosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The survival benefit from <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> appears to be higher in patients with hepatitis C virus (HCV) infection than in those with other underlying risk factors, including hepatitis B virus (HBV), based upon multiple meta-analyses. In the REFLECT trial, there was a trend toward improvement for <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> over sorafenib in the HBV subgroup, but the differences were not significant. (See <a class="local">'Benefit based on etiology of liver disease'</a> below and <a class="local">'Lenvatinib'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> is chosen, to improve early tolerability, we typically start at 200 mg twice a day and increase the daily dose in 200 mg increments approximately every five days until the target dose of 400 mg twice daily is reached.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">Sorafenib</a> is feasible in conjunction with immunosuppressive therapy in patients with a recurrence of HCC following orthotopic liver transplantation (OLT), but it may be more toxic in this setting. Treatment should be closely monitored due to the potential for severe side effects and the need for dose modification. There are no data on the safety and efficacy of <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> in conjunction with immunosuppressive therapy in patients with an HCC recurrence after OLT. (See <a class="local">'Efficacy following TACE or liver transplantation'</a> below.)</p><p></p><p class="bulletIndent1">The safety and benefit of combining <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> or <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> with cytotoxic chemotherapy are not yet definitively established, and we suggest against these strategies outside of the context of a clinical trial. (See <a class="local">'Is there a role for sorafenib plus chemotherapy?'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>These recommendations assume that patients have access to all available therapies. Molecularly targeted and immunotherapy agents are expensive. For patients who are unable to obtain these agents, systemic chemotherapy remains an option. (See <a class="local">'Systemic chemotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In general, first-line treatment is continued until disease progression or intolerance. Issues related to response assessment are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/83809.html" rel="external">"Assessment of tumor response in patients receiving systemic and nonsurgical locoregional treatment of hepatocellular cancer", section on 'Measuring tumor dimensions versus tumor viability'</a>.)</p><p></p><p class="headingAnchor" id="H2101137934"><span class="h3">Atezolizumab plus bevacizumab</span><span class="headingEndMark"> — </span>Combined therapy with <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> has been shown to improve survival as compared with front-line <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> monotherapy. For healthy patients with no worse than Child-Pugh class A cirrhosis  (<a class="graphic graphic_table graphicRef78401" href="/d/graphic/78401.html" rel="external">table 1</a>), an excellent performance status, who have no contraindications to bevacizumab, and have not recurred following liver transplantation, we suggest atezolizumab plus bevacizumab rather than sorafenib monotherapy. This recommendation is consistent with a year 2020 guideline from ASCO [<a href="#rid23">23</a>], year 2021 guidelines from the Society for Immunotherapy of Cancer [<a href="#rid24">24</a>], <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nccn.org%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fwvx5IPN35zkS0nv%2FWmNhBY%3D&amp;TOPIC_ID=2486" target="_blank">the NCCN</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS0168827821022236&amp;token=vdCs7dqmABYrTYLl86e3UDwt2BFE9AyeKZI%2FKeB1WiFrASMf1Wqg91XLB96RnJYMaO2F3vFiU%2BC3yMz8jZgpTh1So9j8RS%2B7MjP8Vlv3jCs%3D&amp;TOPIC_ID=2486" target="_blank">the Barcelona Clinic Liver Cancer</a>, a position paper from the European Association for Study of the Liver [<a href="#rid25">25</a>], and the American Gastroenterological Association [<a href="#rid25">25</a>]. However, the survival benefit compared with other first-line treatment options must be balanced by the higher cost for dual antibody therapy and the potential for adverse events.</p><p>Immunotherapy approaches should be avoided in patients who recur following liver transplantation because of the high rate of allograft rejection. (See <a class="local">'Checkpoint inhibitor immunotherapy'</a> below.)</p><p><a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">Atezolizumab</a> is, a humanized monoclonal antibody immune checkpoint inhibitor that binds to programmed cell death ligand 1 (PD-L1), and <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> is a monoclonal antibody targeting vascular endothelial growth factor (VEGF); there are increasing data to support this combination for first-line treatment of advanced HCC [<a href="#rid26">26-28</a>]. Combination therapy was directly compared with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> monotherapy in the phase III IMBrave 150 trial, which randomly assigned 501 previously untreated patients with advanced unresectable HCC and no worse than Child-Pugh class A cirrhosis 2:1 to atezolizumab (1200 mg intravenous [IV] every three weeks) plus bevacizumab (15 mg/kg IV every three weeks, after atezolizumab) or to sorafenib (400 mg twice daily) [<a href="#rid27">27</a>]. Due to the risk of bleeding, patients enrolled in this trial were required to have undergone esophagogastroduodenoscopy within six months of treatment initiation, and to have treatment of esophageal varices, when necessary. The trial excluded patients who had a myocardial infarction or stroke with the previous three months, were on therapeutic anticoagulation, or had coinfection with HCV or HBV.</p><p>In the latest analysis, at a median follow-up of 15.6 months, median OS with combined therapy was significantly better (19.2 versus 13.4 months, estimated HR for death 0.66, 95% CI 0.52-0.85) [<a href="#rid29">29</a>]. ORRs were nearly threefold higher with combined therapy (30 versus 11 percent). Treatment-related grade 3 or 4 adverse events occurred in a similar percentage of patients in each group (43 versus 46 percent), but hypertension, transaminase elevation, and proteinuria were more frequent with combined therapy; diarrhea was more common with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>.</p><p>In a separate analysis of patient-reported outcomes from this trial, patients who received <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> reported significantly longer delays in median time to deterioration of quality of life (not estimable versus 4.2 months), physical functioning (13.1 versus 5.6 months), and role functioning (9.1 versus 4.3 months) [<a href="#rid28">28</a>]. Combination therapy was also associated with a reduced risk of deterioration of several disease-related symptoms (eg, anorexia, diarrhea, fatigue, pain) compared with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> alone.</p><p>Largely based upon these data, the combination of <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> was approved by the US FDA on May 29, 2020, for treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy. Further support for first-line atezolizumab plus bevacizumab was provided in a year 2020 network meta-analysis of eight trials of molecularly targeted therapy and immunotherapy in the first-line setting (totaling 6290 patients), which concluded that OS was superior for combination of atezolizumab plus bevacizumab compared with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> (HR 0.58, 95% CI 0.42-0.80), <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> (HR 0.63, 95% CI 0.44-0.89), and <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> (HR 0.68, 95% CI 0.48-0.98) [<a href="#rid30">30</a>].</p><p>Few data are available on the safety of immunotherapy following liver transplantation; however, allograft rejection rates may be as high as 39 percent because of stimulation of the host immune response by these agents [<a href="#rid31">31</a>]. Based on these data, immunotherapy approaches should be avoided in patients who recur following transplantation.</p><p class="headingAnchor" id="H1620492894"><span class="h3">Tremelimumab plus durvalumab</span><span class="headingEndMark"> — </span>Combined therapy with <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a> plus a priming dose of <a class="drug drug_general" data-topicid="139983" href="/d/drug information/139983.html" rel="external">tremelimumab</a> has been shown to improve survival over first-line <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> monotherapy. For healthy patients with no worse than Child-Pugh class A cirrhosis  (<a class="graphic graphic_table graphicRef78401" href="/d/graphic/78401.html" rel="external">table 1</a>), an excellent performance status, have not recurred following liver transplantation, and are unable to receive <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, tremelimumab plus durvalumab is an alternative to <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus bevacizumab.</p><p>Combinations of <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a>, an anti-PD-L1 monoclonal antibody, plus a single priming dose of the anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody <a class="drug drug_general" data-topicid="139983" href="/d/drug information/139983.html" rel="external">tremelimumab</a> appear to be tolerable and clinically active in patients who progressed on, were intolerant to, or refused <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> [<a href="#rid32">32</a>]. The comparative efficacy of this regimen for first-line therapy was addressed in the phase III HIMALAYA trial, in which 1171 patients with no worse than Child-Pugh class A cirrhosis and ineligible for locoregional therapy were randomly assigned to a single dose of tremelimumab (300 mg) plus durvalumab (1500 mg followed by durvalumab alone [1500 mg every four weeks]), or durvalumab alone (1500 mg every four weeks), or sorafenib (400 mg twice daily); enrollment to a fourth arm, tremelimumab 75 mg every four weeks plus durvalumab 1500 mg every four weeks was discontinued when interim analysis suggested similar results to durvalumab alone [<a href="#rid33">33</a>]. Combined therapy with durvalumab plus a single priming dose of tremelimumab provided significantly longer median OS compared with sorafenib (16.4 versus 13.8 months, HR for death 0.78, 95% CI 0.65-0.93). Combined therapy was also associated with a higher objective response rate (20 versus 5 percent) and three-year OS (31 versus 20 percent), although similar median progression-free survival (PFS; 3.8 versus 4.1 months). There was also a trend towards better median OS with durvalumab monotherapy compared with sorafenib alone. These results are described below. (See <a class="local">'Durvalumab'</a> below.)</p><p>Largely based on these results, the US FDA has approved the combination of <a class="drug drug_general" data-topicid="139983" href="/d/drug information/139983.html" rel="external">tremelimumab</a> plus <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a> for patients with unresectable HCC [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H432325175"><span class="h3">Lenvatinib</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lenvatinib</strong><strong> alone</strong> – In the REFLECT trial, <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> was shown to be noninferior to first-line <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, which improves survival over supportive care alone. For most patients who are ineligible for or lack access to <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> or <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a> plus <a class="drug drug_general" data-topicid="139983" href="/d/drug information/139983.html" rel="external">tremelimumab</a>, we prefer lenvatinib over sorafenib because in the REFLECT trial, compared with sorafenib, lenvatinib was better tolerated, achieved a higher objective response rate, and delayed the time to tumor progression.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">Lenvatinib</a> is an inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3, as well as fibroblast growth factor receptors (FGFR) 1 to 4, platelet-derived growth factor receptor (PDGFR) alpha, RET, and KIT. Activity in advanced HCC is supported by the following studies:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A phase II trial of first-line <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> (12 mg once daily) in 46 patients with advanced HCC who did not qualify for surgical resection or local therapies reported a partial response in 17 patients (37 percent) and stable disease in an additional 19 patients (41 percent) [<a href="#rid35">35</a>]. Median TTP was 7.8 months, and median OS was 18.7 months. Toxicity was prominent, with hypertension, hand-foot skin reaction, decreased appetite, and proteinuria in 76, 65, 61, and 61 percent, respectively. Dose reductions were needed more often in patients with a low body weight.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A subsequent randomized noninferiority trial (the REFLECT study) compared <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> (12 mg once daily for body weight ≥60 kg, 8 mg daily for &lt;60 kg) versus <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> (400 mg twice daily for all patients) in 954 patients with unresectable HCC and no prior systemic therapy (99 percent Child-Pugh class A) [<a href="#rid36">36</a>]. Patients with involvement of &gt;50 percent of the liver or invasion of the main portal vein or biliary tree were excluded. The predefined noninferiority margin (primary endpoint OS) was 1.08. Lenvatinib was noninferior to sorafenib for median OS, the main endpoint (13.6 versus 12.3 months, HR 0.92, 95% CI 0.79-1.06), the objective response rate was higher (24 versus 9 percent), and median TTP was longer (7.4 versus 3.7 months, HR 0.66, 95% CI 0.57-0.77). From a toxicity standpoint, the rate of grade 3 or 4 hypertension was higher with lenvatinib (23 versus 14 percent), while hand-foot skin reaction was more frequent with sorafenib (52 versus 37 percent any grade, 11 versus 3 percent grade 3 or worse), as was alopecia of any grade (25 versus 3 percent).</p><p></p><p class="bulletIndent1">Largely based on the REFLECT trial, <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> was approved in Japan in March 2018 for treatment of unresectable HCC, and it received approval in the United States for first-line treatment of unresectable HCC in August 2018. Consensus-based guidelines from the NCCN suggest limiting use of lenvatinib to individuals with no worse than Child-Pugh class A cirrhosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other </strong><strong>lenvatinib</strong><strong>-based regimens</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lenvatinib</strong><strong> plus </strong><strong>pembrolizumab</strong> – We do not offer the combination of <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> as initial therapy for advanced hepatocellular carcinoma. Although initial studies suggested clinical benefit for this combination [<a href="#rid37">37</a>], the addition of pembrolizumab to lenvatinib did not meet the prespecified boundaries for PFS and OS in a randomized phase III trial (LEAP-002) [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lenvatinib</strong><strong> plus TACE</strong> – Additional experience with <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus TACE is needed in Western populations, in which the cause of HCC is more often alcoholic cirrhosis than HBV, before it can be concluded that this combination is a preferred approach over systemic therapy alone, especially upfront immunotherapy.</p><p></p><p class="bulletIndent2">Better outcomes with combined <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus TACE versus lenvatinib alone were suggested in the Chinese phase III LAUNCH trial in which 338 patients with advanced HCC (predominantly HBV-related) and no prior local or systemic treatment were randomly assigned to lenvatinib or lenvatinib plus "on-demand" TACE [<a href="#rid7">7</a>]. Although median OS was significantly longer with combined therapy (17.8 versus 11.5 months, HR 0.45, 95% CI 0.34-0.55), grade 3 or 4 adverse events were also more common. This trial is described in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2489.html" rel="external">"Overview of treatment approaches for hepatocellular carcinoma", section on 'Lenvatinib alone or with TACE'</a>.)</p><p></p><p class="headingAnchor" id="H477044332"><span class="h3">Sorafenib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">Sorafenib</a> has been shown to improve survival over best supportive care alone. Sorafenib is an option for first-line therapy in individuals who are not eligible or lack access to front-line <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, and for those with no worse than Child-Pugh class B7 cirrhosis  (<a class="graphic graphic_table graphicRef78401" href="/d/graphic/78401.html" rel="external">table 1</a>), who are not eligible for <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>. For most patients, we prefer lenvatinib, given its better tolerability, higher response rate, and longer TTP in the REFLECT trial. The safety of this drug in patients with less well-preserved liver function is discussed below. (See <a class="local">'Less fit patients and those with Child-Pugh B cirrhosis'</a> below.)</p><p><a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">Sorafenib</a> (Nexavar) is a multitargeted, orally active small molecule TKI that inhibits Raf kinase and the vascular endothelial growth factor receptor (VEGFR) intracellular kinase pathway [<a href="#rid39">39</a>]. It was the first systemic agent to show an OS benefit for advanced HCC in a placebo-controlled trial (the SHARP trial).</p><p>The following data are available:</p><p class="bulletIndent1"><span class="glyph">●</span>The multicenter European SHARP trial randomly assigned 602 patients with inoperable HCC and Child-Pugh class A cirrhosis to <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> (400 mg twice daily) or placebo [<a href="#rid40">40</a>]. OS, the primary endpoint, was significantly longer in the sorafenib-treated patients (10.7 versus 7.9 months), as was time to radiologic progression (5.5 versus 2.8 months). Similar to the phase II trial described above, ORRs were low according to RECIST (seven partial responses [2 percent]). (See <a class="local">'Response assessment'</a> above.)</p><p></p><p class="bulletIndent1">The only grade 3 or 4 adverse effects that occurred significantly more often in the treated group were diarrhea (8 versus 2 percent) and hand-foot skin reaction (8 versus &lt;1 percent). There were no differences in liver dysfunction or bleeding. The overall incidence of sorafenib-related side effects (particularly dermatologic effects) was low compared with that reported by others [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/2088.html" rel="external">"Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy", section on 'Hand-foot skin reaction'</a>.)</p><p></p><p class="bulletIndent1">These results established <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> monotherapy as the new reference standard systemic treatment for advanced HCC and formed the basis for approval of sorafenib for unresectable HCC in the United States.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The efficacy of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> in Asian patients was the subject of a second placebo-controlled phase III trial in which 226 patients with Child-Pugh class A cirrhosis and no prior systemic therapy for HCC received sorafenib 400 mg twice daily or placebo [<a href="#rid42">42</a>]. Patients receiving sorafenib had significantly better median OS (6.5 versus 4.2 months) and TTP (2.8 versus 1.4 months). Grade 3 or 4 side effects included hand-foot skin reaction (11 percent), diarrhea (6 percent), and fatigue (3 percent).</p><p></p><p class="bulletIndent1">The magnitude of the absolute survival benefit was markedly less in this trial than in the SHARP trial. In fact, the treated group in the Asian trial had a shorter survival duration than the control group in the SHARP trial (6.5 versus 7.9 months) despite the fact that both trials used the same entry criteria. Nevertheless, patients accrued to the Asian study were more ill at the start of therapy than those in the SHARP trial, with generally worse performance statuses and more advanced stages of disease [<a href="#rid43">43</a>].</p><p></p><p class="headingAnchor" id="H1280834826"><span class="h4">Benefit based on etiology of liver disease</span><span class="headingEndMark"> — </span>Treatment benefit from <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> appears to be much higher in patients with HCV than in those with other underlying risk factors. However, whether patients with other etiologies of chronic liver disease should be preferentially offered first-line treatment other than sorafenib (eg, <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>) is unclear; there are no prospective studies that have examined treatment response to any other form of molecularly targeted therapy based on HCC etiology, although preliminary reports suggest that immunotherapy benefit may be limited in patients with nonalcoholic steatohepatitis. (See <a class="local">'Lenvatinib'</a> above and <a class="local">'Predictive markers of response'</a> above.)</p><p>Although the Asia Pacific trial showed a benefit for <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> in HBV-infected patients [<a href="#rid42">42</a>], an increasing body of data suggests that patients with HCV infection as the etiology of their cirrhosis may have a better response to sorafenib compared with those with other underlying causes of cirrhosis [<a href="#rid44">44-47</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In an exploratory analysis of the phase III SHARP trial, although a survival benefit was seen in all subgroups treated with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, the difference in median OS between sorafenib-treated and placebo-treated patients was highest in those with HCV related cirrhosis (6.6 months [14 versus 7.4 months]); it was 3.6 months (9.7 versus 6.1 months) in patients with HBV related cirrhosis and 2.3 months (10.3 versus 8 months) in those with underlying alcohol-related liver disease [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An individual patient data meta-analysis of three phase III trials in which <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> was the control arm [<a href="#rid48">48-50</a>] came to the same conclusion [<a href="#rid45">45</a>]. Hazard ratios (HRs) showed that survival was better with sorafenib only among those patients who were both HBV negative and HCV positive (median unadjusted survival 12.6 versus 10.2 months for the "other" treatments). By contrast, sorafenib did not lead to better survival for patients who were either HBV positive or HCV negative.</p><p></p><p>These differences in outcome according to hepatitis virus type could potentially explain some of the survival differences between the SHARP (in which only 18 percent had HBV) and Asian trials (in which 73 percent had HBV-related HCC) of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>. However, the available data are scant, and further study is needed to establish the influence of underlying liver disease on sorafenib treatment responsiveness. (See <a class="local">'Sorafenib'</a> above.)</p><p>Better predictive biomarkers of response to <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> are needed. Many clinical (ie, dermatologic adverse events [<a href="#rid51">51</a>], hypertension, diarrhea [<a href="#rid52">52,53</a>]), biochemical (eg, baseline levels of aspartate aminotransferase and other plasma biomarkers [<a href="#rid54">54,55</a>]), and molecular [<a href="#rid56">56-58</a>] determinants of outcome have been suggested to predict benefit from sorafenib treatment, but none has been validated and accepted in clinical practice.</p><p class="headingAnchor" id="H4270332507"><span class="h4">Efficacy following TACE or liver transplantation</span><span class="headingEndMark"> — </span>Although limited, the available data support the safety and efficacy of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> after transarterial chemoembolization (TACE). Furthermore, sorafenib might represent a feasible treatment option in conjunction with immunosuppressive therapies in patients with a recurrence of HCC following OLT, but treatment should be closely monitored due to the potential for severe side effects. Dose adjustment may be required.</p><p>Few studies have evaluated the efficacy of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> after TACE. TACE aims to eradicate the blood supply to the tumors and thus, at least in theory, could limit delivery of drug to the liver. However, at least some data support the safety and efficacy of sorafenib in this setting [<a href="#rid59">59</a>].</p><p>On the other hand, several randomized trials have not been able to demonstrate a survival benefit for the addition of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> to TACE versus TACE alone. These studies are addressed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/15589.html" rel="external">"Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates not eligible for local thermal ablation", section on 'Does sorafenib or lenvatinib add benefit to TACE?'</a>.)</p><p>There is less certainty about the risk to benefit ratio of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> in patients with recurrent HCC after OLT; in particular, there are sparse data on the safety of combining sorafenib with immunosuppressive therapies, such as mechanistic (previously called mammalian) target of rapamycin (mTOR) or calcineurin inhibitors. The following data are available:</p><p class="bulletIndent1"><span class="glyph">●</span>The largest experience comes from an open-label cohort study of 26 patients with an HCC recurrence after OLT who were not suitable for surgical resection or locoregional treatment and who were receiving a combination of an mTOR inhibitor and <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> [<a href="#rid60">60</a>]. Immunosuppressive therapy was initially switched to an mTOR inhibitor (in view of accumulating data suggesting an antiproliferative effect against HCC as compared with calcineurin inhibitors), with sorafenib started approximately 1.1 to 1.4 months later. (See  <a class="medical medical_review" href="/d/html/2490.html" rel="external">"Liver transplantation for hepatocellular carcinoma", section on 'Degree and type of immunosuppression'</a>.)</p><p></p><p class="bulletIndent1">Ten of 26 patients started <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> at a dose of 800 mg daily, while 16 started at 400 mg daily. The overall disease control rate was 54 percent, median TTP was 6.8 months, and median OS was 19.3 months. There were only two cases of grade 3 or 4 hyperglycemia and one case of grade 3 or 4 mucositis thought possibly related to the mTOR inhibitor. The most common severe adverse event probably related to sorafenib was diarrhea (13 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On the other hand, higher rates of treatment-related toxicity have been noted by others [<a href="#rid61">61-63</a>]. As an example, in a review of 20 patients who experienced a tumor recurrence after OLT for HCC, 13 received <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>; calcineurin inhibitors were continued in four patients and were switched to an mTOR inhibitor in nine [<a href="#rid61">61</a>]. Side effects (mainly acute hepatitis, diarrhea, hand-foot skin reaction, and myelosuppression) prevented full dosing of sorafenib. Grade 3 to 4 adverse events were observed in 92 percent of patients, necessitating discontinuation of sorafenib in 77 percent. However, among patients receiving sorafenib plus an mTOR inhibitor, one patient achieved a partial response and four achieved stable disease.</p><p></p><p class="headingAnchor" id="H1255471126"><span class="h4">Side effects</span><span class="headingEndMark"> — </span>Side effects of antiangiogenic TKIs, such as <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, may include hypertension, renal toxicity, arterial thromboembolism, bleeding, cardiotoxicity, thyroid dysfunction, hand-foot skin reaction, rash, pruritus, alopecia, problems with wound healing, potentially fatal hepatotoxicity, toxic/metabolic encephalopathy, and muscle wasting. (See  <a class="medical medical_review" href="/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a> and  <a class="medical medical_review" href="/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a> and  <a class="medical medical_review" href="/d/html/2088.html" rel="external">"Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy", section on 'VEGFR/PDGFR inhibitors'</a> and  <a class="medical medical_review" href="/d/html/2825.html" rel="external">"Neurologic complications of cancer treatment with molecularly targeted and biologic agents", section on 'Axitinib, cabozantinib, lenvatinib, pazopanib, selpercatinib, sorafenib, sunitinib, and tivozanib'</a>.)</p><p><a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">Sorafenib</a> has been associated with potentially fatal liver toxicity that is characterized predominantly by a hepatocellular pattern of liver damage with significant increases in transaminases, although this is rare; uncommonly, elevations in the international normalized ratio or hyperbilirubinemia may occur. Liver function tests should be monitored regularly during treatment. If transaminases are significantly increased without alternative explanation, such as viral hepatitis or progressing underlying malignancy, sorafenib should be discontinued. (See  <a class="medical medical_review" href="/d/html/128144.html" rel="external">"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Molecularly targeted agents", section on 'Sorafenib'</a>.)</p><p class="headingAnchor" id="H1522434372"><span class="h4">Is there a role for sorafenib plus chemotherapy?</span><span class="headingEndMark"> — </span>There is no established role for combining <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> with cytotoxic chemotherapy as initial treatment for advanced HCC. We do not pursue this approach outside of a clinical trial. Although a phase II trial suggested clinical benefit for the addition of sorafenib to <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> [<a href="#rid64">64</a>], an overall survival benefit could not be confirmed in a randomized phase III trial, Cancer and Leukemia Group B (CALGB) trial 80802 [<a href="#rid65">65</a>]. The study was stopped prematurely by the data monitoring safety board after a planned interim analysis suggested futility for the combination.</p><p>Another randomized phase II trial (PRODIGE 10) also failed to demonstrate a PFS benefit for the addition of <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> and <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> (GEMOX) to <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> as initial therapy for advanced HCC [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H2509857380"><span class="h3">Donafenib</span><span class="headingEndMark"> — </span>Donafenib is a derivative of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> with a more favorable pharmacokinetic profile, largely because of reduced susceptibility to hepatic drug metabolizing enzymes [<a href="#rid67">67</a>]. Modestly superior efficacy and tolerability with donafenib was shown in a Chinese trial directly comparing both drugs for first-line treatment of advanced HCC [<a href="#rid68">68</a>]. Donafenib is approved in China for treatment of patients with unresectable HCC who have not previously received systemic treatment [<a href="#rid69">69</a>]; however, it is not available elsewhere.</p><p class="headingAnchor" id="H592674441"><span class="h3">Immunotherapy alone</span></p><p class="headingAnchor" id="H3822512818"><span class="h4">Durvalumab</span><span class="headingEndMark"> — </span>We consider <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a> monotherapy to represent a reasonable alternative to <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> if patients are ineligible for combined therapy with either <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> or durvalumab plus <a class="drug drug_general" data-topicid="139983" href="/d/drug information/139983.html" rel="external">tremelimumab</a>.</p><p><a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">Durvalumab</a> is an anti-PD-L1 monoclonal antibody. The noninferiority of durvalumab monotherapy over <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> for first-line treatment of advanced HCC was shown in a preliminary report of the three-arm HIMALAYA trial, which compared sorafenib versus durvalumab alone or with <a class="drug drug_general" data-topicid="139983" href="/d/drug information/139983.html" rel="external">tremelimumab</a>. The results of combined therapy versus sorafenib alone are described above. (See <a class="local">'Tremelimumab plus durvalumab'</a> above.)</p><p>Briefly, this trial randomly assigned 1171 patients with no worse than Child-Pugh class A cirrhosis and ineligible for locoregional therapy to a single dose of <a class="drug drug_general" data-topicid="139983" href="/d/drug information/139983.html" rel="external">tremelimumab</a> (300 mg) plus <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a> (1500 mg followed by durvalumab alone [1500 mg every four weeks]), durvalumab alone (1500 mg every four weeks), or <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> (400 mg twice daily) [<a href="#rid33">33</a>]. Compared with sorafenib alone, durvalumab monotherapy was judged noninferior (median OS 16.6 versus 13.8 months, HR 0.86, 95% CI 0.73-1.03). Other benefits for durvalumab included a higher objective response rate (17 versus 5 percent), lower rate of grade 3 or 4 treatment-related adverse effects (13 versus 37 percent), and fewer patients discontinuing therapy because of adverse effects (4 versus 11 percent). Compared with combined durvalumab plus tremelimumab, median OS was similar with durvalumab monotherapy (median 16.4 versus 16.6 months), but three-year survival rates still favored combined therapy over durvalumab alone (30.7 versus 24.7 percent).</p><p class="headingAnchor" id="H2182697493"><span class="h4">Nivolumab and pembrolizumab</span><span class="headingEndMark"> — </span>First-line <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> could be considered for patients with advanced HCC in whom TKIs and antiangiogenic drugs are contraindicated or unavailable, but nivolumab monotherapy is not approved either in the United States or Europe for front-line therapy. (See <a class="local">'Pembrolizumab'</a> below and <a class="local">'Nivolumab plus ipilimumab'</a> below.)</p><p>The immune checkpoint inhibitors <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> and <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> are approved for treatment of HCC in patients previously treated with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>. (See <a class="local">'Checkpoint inhibitor immunotherapy'</a> below.)</p><p>The benefit of first-line immunotherapy for previously untreated patients with advanced HCC remains uncertain:</p><p class="bulletIndent1"><span class="glyph">●</span>Benefit for first-line <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> was suggested in an early report of a cohort of 51 patients enrolled in the uncontrolled phase II KEYNOTE-224 trial who had not received any prior systemic therapy for advanced HCC [<a href="#rid70">70</a>]. The objective response rate was 16 percent (all partial responses), and the median duration of response was 16 months (range 3 to 24+ months). The median PFS and OS durations were 4 and 17 months, respectively. There were no new toxicity signals, and the most common treatment-related adverse events were diarrhea, fatigue, hypothyroidism, and myalgias. One patient died with immune-mediated myocarditis and hepatitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>First-line <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> was directly compared with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> in the phase III CheckMate 459 trial, which enrolled 743 patients with advanced, previously untreated HCC [<a href="#rid71">71</a>]. At a minimum follow-up of 22.8 months, nivolumab was associated with a twofold higher objective response rate (15 versus 7 percent) and more complete responses (4 versus 1 percent), but this did not translate into a significant benefit in either PFS (median 3.7 versus 3.8 months) or OS (median 16.4 versus 14.7 months; HR 0.85, 95% CI 0.72-1.02). Grade 3 or 4 treatment-related serious adverse events were reported in a similar number of nivolumab- and sorafenib-treatment patients (12 versus 11 percent), and there was no significant difference in the number of patients who discontinued therapy because of side effects.</p><p></p><p class="headingAnchor" id="H2381424271"><span class="h3">Other regimens</span><span class="headingEndMark"> — </span>Some regimens are effective initial therapies for advanced HCC but are only available in certain countries, while others are not used due to lack of efficacy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Camrelizumab plus rivoceranib (apatinib)</strong> – For fit patients with advanced or metastatic HCC and no worse than Child-Pugh class A cirrhosis, initial therapy with camrelizumab plus rivoceranib (ie, apatinib) improved PFS and OS relative to <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> in an international phase III trial. However, this combination is not available outside of China.</p><p></p><p class="bulletIndent1">In an international, open-label phase III trial (CARES-310), 543 patients with systemic-therapy naïve, unresectable or metastatic HCC and Child-Pugh Class A liver function were randomly assigned to either camrelizumab (a programmed cell death protein 1 [PD-1] inhibitor) plus rivoceranib (ie, apatinib, an antiangiogenic agent that targets VEGFR2) or <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> [<a href="#rid72">72</a>]. Patients were included from China, Hong Kong, Taiwan, and South Korea (83 percent) as well as Europe and the United States (17 percent). Compared with sorafenib alone, camrelizumab plus rivoceranib improved PFS at median follow-up of eight months (5.6 versus 3.7 months, HR 0.52, 95% CI 0.41-0.65), OS at median follow-up of 15 months (22 versus 15 months, HR 0.62, 95% CI 0.49-0.80), and objective response rates (25 versus 6 percent). Grade ≥3 toxicity rates were higher for the combination (81 versus 52 percent).</p><p></p><p class="bulletIndent1">Camrelizumab and rivoceranib is approved as a first-line treatment for patients with liver cancer by the Chinese National Medical Products Administration (NMPA) [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sintilimab plus </strong><strong>bevacizumab</strong> — The combination of sintilimab, a PD-1 inhibitor, with a <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> biosimilar improved OS and PFS compared with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> alone in a randomized trial (ORIENT-32) conducted in China [<a href="#rid74">74</a>]. Sintilimab is available in China but does not have regulatory approval in the United States.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cabozantinib</strong><strong> plus </strong><strong>atezolizumab</strong> — We do not use the combination of <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> plus <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> as initial systemic therapy for advanced HCC. In a randomized phase III trial (COSMIC-312) of 837 patients with systemic therapy-naïve advanced HCC, cabozantinib plus atezolizumab failed to improve OS and increased treatment-related toxicity relative to <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> [<a href="#rid75">75</a>].</p><p></p><p class="headingAnchor" id="H740680217"><span class="h2">Second-line therapy</span><span class="headingEndMark"> — </span>Second-line therapy is an option for patients whose tumors progress while on first-line therapy and whose performance status and liver function are sufficient to tolerate it. The best regimen is not established, and it depends, in part, on what was administered first-line. Most notably, all of the data examining the benefit of any second-line immunotherapy treatment were derived in patients initially treated with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, and there are no data on efficacy in those initially treated with <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>. There are also no data to inform optimal sequencing of later lines of treatment after any first-line regimen [<a href="#rid76">76</a>]. The side effect profile of each individual regimen must be carefully considered in patients who have advanced liver disease and/or a short life expectancy.</p><p>The availability of effective second-line regimens has prompted a shift away from symptomatic progression as an endpoint to stop first-line therapy (as was used in the SHARP trial (see <a class="local">'Sorafenib'</a> above)) to radiologic progression as assessed by cross-sectional imaging that assesses both tumor viability and size. However, given the difficulties with radiographic imaging, particularly with molecularly targeted agents, we favor use of clinical status and serial assay of alpha-fetoprotein (AFP), if initially elevated, in conjunction with radiographic imaging if a change in treatment is being considered. (See <a class="local">'Response assessment'</a> above.)</p><p class="headingAnchor" id="H1712452986"><span class="h3">Selection of therapy</span><span class="headingEndMark"> — </span>The following represents our general approach to second-line therapy in suitable patients, which is consistent with ASCO guidelines [<a href="#rid23">23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>We prefer that eligible patients are enrolled in clinical trials testing new treatment strategies, if possible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who are not eligible for clinical trials or if they are not available, options for patients initially treated with <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> or <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a> plus <a class="drug drug_general" data-topicid="139983" href="/d/drug information/139983.html" rel="external">tremelimumab</a> include <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>, <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a>, <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a>, or apatinib, where available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For most patients who have progressed on or are unable to tolerate <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> or <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>, and who have not undergone liver transplantation, we suggest <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> rather than other immunotherapy options or a second tyrosine kinase inhibitor. However, this regimen should not be administered to patients with Child-Pugh class B or C. <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">Pembrolizumab</a> is an appropriate alternative for those who are unable to tolerate the potential toxicities of nivolumab plus ipilimumab. (See <a class="local">'Checkpoint inhibitor immunotherapy'</a> below.)</p><p></p><p class="bulletIndent1">While <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a> and <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> have also been approved for this patient group, immune checkpoint inhibitors have the potential for a higher objective response rate (including some complete responders) and the more favorable side effect profile. The higher response rate may translate into a real life benefit for patients with large or symptomatic tumors and may represent a preferred option for these patients, although this has yet to be confirmed in actual practice. (See <a class="local">'Regorafenib'</a> below and <a class="local">'Checkpoint inhibitor immunotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">Lenvatinib</a> is another option for treatment of patients who have no worse than Child-Pugh class A cirrhosis after failure of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>. However, whether lenvatinib will work after failure of sorafenib is not known; there are no trials to inform this issue. (See <a class="local">'Lenvatinib'</a> above.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">Cabozantinib</a> is another option for treatment of patients who have no worse than Child-Pugh class A cirrhosis, particularly for those who are intolerant of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> or <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a>. (See <a class="local">'Cabozantinib'</a> below.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="94963" href="/d/drug information/94963.html" rel="external">Ramucirumab</a> is another option for the subset of patients with a high AFP level (&gt;400 ng/mL). (See <a class="local">'Ramucirumab'</a> below.)</p><p></p><p class="bulletIndent1">For patients initially treated with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, the choice of any of these TKIs or immunotherapy is empiric, as there are no comparator trials in this setting. A network meta-analysis of five trials of second-line therapy (<a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a>, <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a>, <a class="drug drug_general" data-topicid="94963" href="/d/drug information/94963.html" rel="external">ramucirumab</a>, brivanib) after failure of sorafenib concluded that the OS advantage relative to placebo was limited to second-line regorafenib (HR 0.62, 95% CI 0.51-0.75) and cabozantinib (HR 0.76, 95% CI 0.63-0.92) [<a href="#rid30">30</a>]. Indirect comparisons between the individual drugs were largely uninformative.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have progressed on first-line <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> and who have no worse than Child-Pugh class A cirrhosis, we also prefer <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> with <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, or <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> rather than <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> or another TKI. (See <a class="local">'Nivolumab monotherapy'</a> below and <a class="local">'Pembrolizumab'</a> below.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">Sorafenib</a> is an option after failure of first-line <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>, but whether it will work in this setting is not known.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">Cabozantinib</a> is another option for treatment of patients who have no worse than Child-Pugh class A cirrhosis, particularly for those who are intolerant of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> or <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a>. (See <a class="local">'Cabozantinib'</a> below.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="94963" href="/d/drug information/94963.html" rel="external">Ramucirumab</a> is another option for the subset of patients with a high AFP level (&gt;400 ng/mL). (See <a class="local">'Ramucirumab'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients initially treated with a TKI, <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> is another option for appropriately selected patients. Although there are no data on the efficacy of this combination after failure of a TKI, it is likely that most patients being considered for atezolizumab plus bevacizumab in this setting did not have access to this combination when they started treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>These recommendations assume that patients have access to all available therapies. Molecularly targeted agents and immune checkpoint inhibitors are expensive. For patients who are unable to obtain these agents, systemic chemotherapy remains an option. The best regimen is not established. Options for fit patients include GEMOX, <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">pegylated liposomal doxorubicin</a> (PLD), or <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> monotherapy, especially for jaundiced individuals. (See <a class="local">'Systemic chemotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In general, second-line therapy is continued until radiologic disease progression or intolerance. Issues related to response assessment during therapy are addressed elsewhere. (See  <a class="medical medical_review" href="/d/html/83809.html" rel="external">"Assessment of tumor response in patients receiving systemic and nonsurgical locoregional treatment of hepatocellular cancer", section on 'Measuring tumor dimensions versus tumor viability'</a>.)</p><p></p><p class="headingAnchor" id="H392168110"><span class="h3">Checkpoint inhibitor immunotherapy</span><span class="headingEndMark"> — </span>Immunotherapy is our preferred option for second-line therapy in patients previously treated with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> or <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> who have not undergone liver transplantation. Options include <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> or <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> monotherapy. The role of immunotherapy as a first-line option is discussed above. (See <a class="local">'Nivolumab and pembrolizumab'</a> above.)</p><p>Immunotherapy approaches should be avoided in patients who recur following orthotopic liver transplantation because of the high rate of allograft rejection [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H2385892211"><span class="h4">Nivolumab plus ipilimumab</span><span class="headingEndMark"> — </span>An OS benefit has been shown in the second-line setting for combined <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> compared with nivolumab alone, after progression on <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, and this approach could be considered if immunotherapy was not administered for front-line therapy.</p><p><a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">Nivolumab</a> is a fully human monoclonal antibody that targets the PD-1, restoring T cell immune activity directed against the tumor cell. <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">Ipilimumab</a> is an inhibitor of a different immune checkpoint (CTLA-4), and combined therapy with nivolumab effectively targets two different immune checkpoints that restrain the adaptive immune response. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy"</a>.)</p><p>The efficacy of combined therapy was addressed in the phase I/II CheckMate 040 trial, in which 148 sorafenib-treated patients were randomly assigned to one of three groups: <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> 1 mg/kg plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> 3 mg/kg every three weeks for four doses, followed by nivolumab 240 mg every two weeks; nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every three weeks for four doses, followed by nivolumab 240 mg every two weeks; or nivolumab 3 mg/kg every two weeks plus ipilimumab 1 mg/kg every six weeks [<a href="#rid77">77</a>]. All patients had no worse than Child-Pugh class A cirrhosis. When the three groups were combined, the objective response rate was 31 percent (more than twice as high as what was seen with nivolumab alone [14 percent]), and seven had a complete response. Almost one-third of the responses in each group were still ongoing at 24 months. In the latest analysis, when the three groups were compared, the best outcomes were seen with nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every three weeks, followed by maintenance nivolumab. Of the 50 patients who received this combination, there were 16 objective responses (32 percent), four of which were complete, and the median OS was 22.2 months (versus 12.5 and 12.7 months in the other two groups) [<a href="#rid78">78</a>]. The median duration of response in the three groups was 17.5, 22.2, and 16.6 months, respectively, and the disease control rate was similar in the three groups (54, 43, and 49 percent, respectively).</p><p>Immune-mediated adverse events were also more common in this cohort (10 of 49, 20 percent), median time to onset was 1.3 months [<a href="#rid79">79</a>]. High-dose glucocorticoids were administered to 70 percent (median 14 days), and complete resolution occurred in 70 percent. Of the four patients who reinitiated treatment after symptom improvement, none had recurrence of hepatitis. Other immune-mediated side effects included rash in 35 percent (17 of 49; median time to onset 15 days), adrenal insufficiency in 18 percent (9 of 49; median time to onset 2.8 months), hypothyroidism or thyroiditis in 22 percent (5 of 49; median time to onset 1.4 months), colitis in 10 percent (5 of 49; median time to onset 2 months), pneumonitis in 10 percent (5 of 49; median time to onset 8.3 months), and infusion-related reactions in 8 percent (4 of 49).</p><p>Finally, in all three groups combined, virologic breakthrough, defined as a one-log increase in HBV DNA or HCV RNA from baseline, was observed in 7 of 82 HBV-infected patients (9 percent) and 4 of 39 HCV-infected patients (10 percent) overall. (See <a class="local">'Screen for viral hepatitis'</a> above.)</p><p>Largely based on this study, combination <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> was approved in March 2020 for treatment of HCC in patients previously treated with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> [<a href="#rid80">80</a>]. The recommended doses are nivolumab 1 mg/kg followed by ipilimumab 3 mg/kg on the same day, every three weeks for four doses, then nivolumab alone (240 mg every two weeks or 480 mg every four weeks). Given the higher response rates and durability of responses, for patients with no worse than Child-Pugh class A cirrhosis who are being considered for immunotherapy and who are able to tolerate it, we prefer combined therapy with nivolumab plus ipilimumab over <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> alone.</p><p>Notably, there are no data on the efficacy of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> alone or in combination with <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> in patients previously treated with an anti-PD-L1-targeted therapy such as <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a>.</p><p class="headingAnchor" id="H2947958095"><span class="h4">Pembrolizumab</span><span class="headingEndMark"> — </span>In patients with advanced HCC who have progressed on <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> (a PD-1 inhibitor) is a reasonable alternative to <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> in patients who are unable to tolerate the potential toxicities of such combination immunotherapy.</p><p>The efficacy of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> in advanced HCC refractory to <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> was initially demonstrated in a phase II trial (KEYNOTE-224) [<a href="#rid81">81,82</a>]. In two subsequent placebo-controlled phase III trials, pembrolizumab improved ORRs; it also improved OS and PFS in one of trials conducted in patients from Asia (KEYNOTE-394) [<a href="#rid83">83,84</a>]. Data are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In an international, double-blind phase III trial (KEYNOTE-240), 413 patients with advanced HCC and Child-Pugh class A cirrhosis who had radiographic progression/intolerance of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> were randomly assigned on a 2:1 basis to either <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> or placebo, in addition to best supportive care (BSC) [<a href="#rid83">83</a>]. At median follow-up of approximately 14 months, for pembrolizumab versus placebo, the differences in OS (median 14 versus 11 months, HR 0.78, 95% CI 0.61-0.998) and PFS (median 3 versus 2.8 months, HR 0.72, 95% CI 0.57-0.90) were not statistically significant because prespecified efficacy boundaries were not reached. However, pembrolizumab improved the ORR over placebo (18 versus 4 percent) and had more complete responders (six versus none). Treatment responses to pembrolizumab were also durable (median duration of response 14 months, range 2 to 24+ months).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another double-blind phase III trial (KEYNOTE-394), 413 patients with advanced, treatment-refractory HCC from Asia (mainland China, Hong Kong, the Republic of Korea, Malaysia, and Taiwan) were randomly assigned to either <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> or placebo, in addition to BSC [<a href="#rid84">84</a>]. Patients had Child-Pugh Class A cirrhosis and had either progressed on or were intolerant to <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> or oxaliplatin-based chemotherapy. At median follow-up of 34 months, compared with placebo, pembrolizumab improved PFS (median 2.6 versus 2.3 months, HR 0.74, 95% CI 0.60-0.92) and OS (median 15 versus 13 months, HR 0.79, 95% CI 0.63-0.99). Pembrolizumab also improved ORR over placebo (13 versus 1 percent), including six complete responders (2 percent). The grade ≥3 toxicity rate for pembrolizumab was 14 percent.</p><p></p><p>Based on data from KEYNOTE-394, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 6</a>) was approved by the US Food and Drug Administration (FDA) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1 containing regimen [<a href="#rid85">85</a>]. </p><p class="headingAnchor" id="H956378715"><span class="h4">Nivolumab monotherapy</span><span class="headingEndMark"> — </span>The efficacy of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> monotherapy was addressed in a phase I/II study (CheckMate 040) that included patients with advanced HCC and Child-Pugh class A or B (total score of 7 or less  (<a class="graphic graphic_table graphicRef78401" href="/d/graphic/78401.html" rel="external">table 1</a>)) cirrhosis whose disease had progressed on <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> or who refused or were intolerant of the drug [<a href="#rid86">86</a>]. The combined report included 48 patients treated in the dose-escalation part of the study and 214 in the expansion cohort. In the dose-escalation part, nivolumab was administered IV every two weeks at doses from 0.1 to 10 mg/kg for up to two years; although a maximally tolerated dose was not reached, the expansion cohort was treated at a dose of 3 mg/kg (as long as not HBV infected). Overall, 68 percent of the expansion cohort had received sorafenib previously. Forty-nine of the 255 patients assessable for response had an objective antitumor response to nivolumab (15 percent of the escalated-dose cohort and 20 percent of the expansion cohort), six of which were complete. An additional 50 percent had stable disease. In the dose-escalation group, the median duration of response was 17 months (95% CI 6-24), and the median OS was 15 months. In the expansion cohort, the median duration of response was 9.9 months, and the data were insufficiently mature for calculation of median survival; however, 74 percent of patients remained alive at nine months.</p><p>Most adverse events were mild and transient; the most common grade 3 or 4 toxicities in the 48 patients in the dose-escalation phase were increased aspartate aminotransferase (10 percent), increased alanine aminotransferase (3 percent), increased lipase (3 percent), and increased amylase (2 percent). Immune-mediated hepatitis requiring systemic glucocorticoids occurred in 5 percent of treated patients. Toxicity was similar in the expansion cohort.</p><p>In a later analysis of the entire cohort, the durable benefits of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> were observed both in sorafenib-naïve (objective response rate 23 percent, with 44 percent of responses ongoing) and sorafenib-experienced patients (objective response rate 16 to 19 percent) [<a href="#rid87">87</a>].</p><p>Although the FDA initially granted accelerated approval to <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> for treatment of HCC in patients previously treated with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> in 2017, this approval was withdrawn in 2021 because of the negative findings of the phase III trial directly comparing nivolumab versus sorafenib as first-line therapy (see <a class="local">'Nivolumab and pembrolizumab'</a> above). The European Medicines Agency has not approved nivolumab monotherapy in this setting [<a href="#rid88">88</a>].</p><p class="headingAnchor" id="H1674841407"><span class="h4">Avelumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">Avelumab</a> is an anti-PD-L1 monoclonal antibody that is approved for advanced urothelial, renal cell, and Merkel cell cancer. Efficacy in 30 patients with advanced HCC and no worse than Child-Pugh class A cirrhosis who were previously treated with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> was shown in a phase II trial, in which there were three partial responses (10 percent) and 19 patients (63 percent) with prolonged stable disease [<a href="#rid89">89</a>]. Tumoral overexpression of PD-L1 did not affect the antitumor response. The median time to tumor progression and OS durations were 4.4 and 14.2 months, respectively. Treatment was well tolerated with few grade 3 adverse events.</p><p class="headingAnchor" id="H2804028263"><span class="h4">Toxicity considerations and response assessment</span><span class="headingEndMark"> — </span>Notably, although patients with HCC who are treated with immune checkpoint inhibitors have a substantial increase in transaminases as compared with patients receiving these drugs for other indications (eg, lung cancer, melanoma), this has not translated into premature treatment discontinuation or treatment-related mortality [<a href="#rid77">77,90</a>]. Nevertheless, liver function tests should be monitored during therapy with these agents. (See  <a class="medical medical_review" href="/d/html/134862.html" rel="external">"Hepatic, pancreatic, and rare gastrointestinal complications of immune checkpoint inhibitor therapy", section on 'Hepatotoxicity'</a>.)</p><p>The patterns of response to treatment with immunotherapy differ from those with molecularly targeted agents or cytotoxic chemotherapy. Patients may appear to have a transient worsening of disease, manifested by either progression of known lesions or the appearance of new lesions, before disease stabilizes or regresses. In addition, responses can take appreciably longer to become apparent compared with cytotoxic therapy. (See <a class="local">'Immunotherapy'</a> above.)</p><p>Immune-related response criteria have been proposed to properly recognize the nontraditional patterns of response occasionally seen with checkpoint inhibitors and some other immunotherapies  (<a class="graphic graphic_table graphicRef116649" href="/d/graphic/116649.html" rel="external">table 7</a>) [<a href="#rid91">91</a>]. This subject is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'Immunotherapy response criteria'</a>.)</p><p class="headingAnchor" id="H2159105459"><span class="h3">Tyrosine kinase inhibitors</span></p><p class="headingAnchor" id="H998007681"><span class="h4">Regorafenib</span><span class="headingEndMark"> — </span>For patients progressing on <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a> has been shown to improve OS over best supportive care alone. We consider regorafenib to be an alternative to <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>/<a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> or <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> monotherapy to second-line treatment after progression on sorafenib for patients who seemed to benefit from sorafenib, who maintain a good performance status and adequate liver function, and who are willing to trade treatment-related morbidity for the possibility of a small gain in median OS. However, for most patients we prefer immunotherapy. We would not consider regorafenib an appropriate option for patients who were intolerant of sorafenib. Regorafenib is also an option for patients progressing after first-line immunotherapy.</p><p><a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">Regorafenib</a> is an orally active inhibitor of angiogenic (including VEGFR-1, VEGFR-2, and VEGFR-3), stromal, and oncogenic receptor tyrosine kinases. It is structurally similar to <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> and targets a variety of kinases implicated in angiogenic and tumor growth-promoting pathways. A benefit for regorafenib in patients progressing after first-line treatment with sorafenib was suggested in the RESORCE trial, in which 573 patients who received sorafenib for at least 20 days at a dose of at least 400 mg daily, who had radiologic progression, and who maintained a performance status of 0 to 1  (<a class="graphic graphic_table graphicRef72901" href="/d/graphic/72901.html" rel="external">table 5</a>) and Child-Pugh class A liver function  (<a class="graphic graphic_table graphicRef78401" href="/d/graphic/78401.html" rel="external">table 1</a>) were randomly assigned to regorafenib (160 mg once daily for three weeks on and one week off) or placebo [<a href="#rid92">92</a>]. Regorafenib was associated with significant prolongation in median OS (10.6 versus 7.8 months, HR for death 0.63), as well as significantly higher rates of objective antitumor response (11 versus 4 percent, none complete) and disease control (objective response plus stable disease; 65 versus 36 percent). Response assessment utilized modified RECIST for HCC. (See <a class="local">'Response assessment'</a> above.)</p><p>Treatment was relatively well tolerated; among the grade 3 or 4 adverse events occurring more often with <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a> were hypertension (15 versus 5 percent), hand-foot skin reaction (13 versus 1 percent), fatigue (9 versus 5 percent), and diarrhea (3 versus 0 percent). Sixty-eight percent of patients treated with regorafenib required dose modification for adverse events (compared with 31 percent of the placebo group).</p><p>Largely based on these data, in April 2017, the FDA expanded the indications for <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a> to include patients with HCC who had been previously treated with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>.</p><p>Similar to <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, we start at lower-than-recommended doses of <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a> (typically 80 mg once daily) and escalate the dose as tolerated. Consensus-based guidelines from the NCCN recommend considering regorafenib only for patients with no worse than Child-Pugh class A cirrhosis.</p><p class="headingAnchor" id="H3302475028"><span class="h4">Cabozantinib</span><span class="headingEndMark"> — </span>For patients previously treated with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> has been shown to improve OS compared with supportive care alone. We consider cabozantinib to be an alternative to <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>/<a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> or <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> monotherapy for second-line treatment after progression on sorafenib. However, for most patients we prefer immunotherapy. Cabozantinib is also an option for patients progressing after first-line immunotherapy.</p><p><a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">Cabozantinib</a> is another potent inhibitor of several receptor tyrosine kinases, including the hepatocyte growth factor/c-MET, VEGFR-1, VEGFR-2, and VEGFR-3 [<a href="#rid93">93</a>]. High levels of MET expression have been associated with previous <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> treatment in patients with HCC, and with sorafenib resistance in preclinical models [<a href="#rid94">94-96</a>].</p><p>Efficacy of <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> in patients with previously treated advanced HCC was shown in the phase III CELESTIAL trial, in which 707 patients with advanced and progressing HCC and no worse than Child-Pugh class A cirrhosis were randomly assigned to cabozantinib or placebo [<a href="#rid97">97</a>]. In the population of patients receiving second- or third-line treatment after prior treatment with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, median OS was significantly better with cabozantinib (10.2 versus 8.0 months), and the difference was more pronounced when the analysis was limited to patients whose only prior therapy was sorafenib (median OS 11.3 versus 7.2 months). In a later analysis, cabozantinib improved outcomes versus placebo across a range of baseline AFP levels [<a href="#rid98">98</a>].</p><p>The most common grade 3 or 4 adverse events with <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> were palmar-plantar erythrodysesthesia (17 versus 0 percent in the placebo group), hypertension (16 versus 2 percent), increased aspartate aminotransferase (12 versus 7 percent), fatigue (10 versus 4 percent), and diarrhea (10 versus 2 percent) [<a href="#rid97">97</a>].</p><p>Based on these data, <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> was approved in January 2019 for treatment of patients with HCC who have been previously treated with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>. Consensus-based guidelines from the NCCN recommend considering cabozantinib only for patients with no worse than Child-Pugh class A cirrhosis, although safety and efficacy has been suggested in patients with albumin-bilirubin grade 1 or 2 hepatic dysfunction (<a class="calc calc_professional" href="/d/html/100996.html" rel="external">calculator 1</a>) [<a href="#rid99">99</a>]. (See <a class="local">'Estimate life expectancy and assess liver function'</a> above and  <a class="medical medical_review" href="/d/html/2476.html" rel="external">"Staging and prognostic factors in hepatocellular carcinoma", section on 'Albumin-bilirubin (ALBI) score'</a>.)</p><p class="headingAnchor" id="H2631652996"><span class="h4">Ramucirumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="94963" href="/d/drug information/94963.html" rel="external">Ramucirumab</a> is an appropriate second-line option after failure of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> or front-line immunotherapy, but benefit appears limited to those with initially high AFP levels.</p><p><a class="drug drug_general" data-topicid="94963" href="/d/drug information/94963.html" rel="external">Ramucirumab</a> is a recombinant monoclonal antibody of the immunoglobulin G subclass 1 (IgG1) class that binds to VEGFR-2, blocking receptor activation. A modest degree of activity in patients with no prior systemic treatment was suggested in a phase II trial of 42 patients; the objective response rate was 10 percent, and median OS was 12 months [<a href="#rid100">100</a>]. However, in the absence of a trial directly comparing ramucirumab with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, first-line ramucirumab cannot be considered a standard approach.</p><p>On the other hand, <a class="drug drug_general" data-topicid="94963" href="/d/drug information/94963.html" rel="external">ramucirumab</a> is an appropriate second-line option after failure of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, but benefit appears limited to those with initially high AFP levels:</p><p class="bulletIndent1"><span class="glyph">●</span>A trial of <a class="drug drug_general" data-topicid="94963" href="/d/drug information/94963.html" rel="external">ramucirumab</a> versus placebo in patients with advanced HCC following first-line therapy with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> (the REACH trial) failed to show a significant survival advantage relative to placebo (median OS 9.2 versus 7.6 months) [<a href="#rid101">101</a>]. An unplanned subset analysis suggested the potential for a survival benefit in patients with a high initial level of AFP (&gt;400 ng/mL) at diagnosis (median survival 7.8 versus 4.2 months).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Benefit in this subgroup was confirmed in a randomized phase III trial (the REACH-2 trial), which randomly assigned 292 patients with HCC, no worse than Child-Pugh class A cirrhosis, and a serum AFP ≥400 ng/mL who had disease progression on first-line <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> to <a class="drug drug_general" data-topicid="94963" href="/d/drug information/94963.html" rel="external">ramucirumab</a> versus placebo [<a href="#rid102">102</a>]. Ramucirumab was associated with significantly better OS (8.5 versus 7.3 months, HR 0.71, 95% CI 0.53-0.95), although the magnitude of benefit (1.2 months) was numerically less than that seen in the subset of patients with a high AFP enrolled in the REACH trial (3.6 months). Ramucirumab also was associated with a higher objective response rate (5 versus 1 percent) and overall disease control rate (60 versus 39 percent). One potential advantage of ramucirumab over other molecularly targeted treatments for second-line therapy after progression on sorafenib is the absence of hand-foot skin reaction.</p><p></p><p class="bulletIndent1">Largely based on this trial, <a class="drug drug_general" data-topicid="94963" href="/d/drug information/94963.html" rel="external">ramucirumab</a> was approved in May 2019 for second-line treatment of HCC in patients who have an AFP level ≥400 ng/mL and have been previously treated with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> [<a href="#rid103">103</a>].</p><p></p><p class="headingAnchor" id="H1239827226"><span class="h4">Apatinib</span><span class="headingEndMark"> — </span>Apatinib is an orally active VEGFR-2 inhibitor that is approved for second-line treatment of advanced gastric cancer in China; it is not available in the United States or Europe.</p><p>Efficacy for second-line treatment of advanced HCC after failure of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> and oxaliplatin-based chemotherapy was shown in a phase III randomized placebo-controlled trial of 393 patients with no worse than Child-Pugh class A or B (≤7) cirrhosis [<a href="#rid104">104</a>]. Apatinib improved OS (median 8.7 versus 6.8 months HR 0.785, 95% CI 0.617-0.998) and PFS, and was well tolerated.</p><p class="headingAnchor" id="H340357065"><span class="h1">LESS FIT PATIENTS AND THOSE WITH CHILD-PUGH B CIRRHOSIS</span><span class="headingEndMark"> — </span>For patients who can tolerate it, we suggest <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> monotherapy rather than systemic chemotherapy as long as the total Child-Pugh score is &lt;7  (<a class="graphic graphic_table graphicRef78401" href="/d/graphic/78401.html" rel="external">table 1</a>). Another option for individuals with no worse than Child-Pugh B7 cirrhosis is <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>.</p><p>The best way to manage systemic therapy in patients with Child-Pugh class B cirrhosis is not established. The vast majority of studies of immunotherapy or molecularly targeted therapy have been carried out in populations with preserved liver function (ie, no worse than Child-Pugh class A cirrhosis). There are few data on the safety and efficacy of any of these agents in patients with less well preserved liver function [<a href="#rid105">105-108</a>]. The majority of the published experience in this group is with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>.</p><p class="headingAnchor" id="H4285660365"><span class="h2">Sorafenib</span><span class="headingEndMark"> — </span>The patients enrolled in the original first-line <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> trials had predominantly (over 95 percent) Child-Pugh class A cirrhosis. Despite the specific population studied in the SHARP trial, the original US Food and Drug Administration approval of sorafenib for HCC in the United States did not specify the underlying cirrhosis state. (See <a class="local">'Sorafenib'</a> above.)</p><p>However, the majority of patients with HCC have underlying cirrhosis and, therefore, competing causes of death from progressive HCC versus worsening cirrhosis. In a systematic review of 118 studies of patients with cirrhosis and no HCC, the one- and two-year survival rates for patients with Child-Pugh class A, B, or C cirrhosis were 95 and 90, 80 and 70, and 45 and 38 percent, respectively [<a href="#rid109">109</a>]. Death from cirrhosis could potentially mask treatment-related antitumor effect.</p><p>Furthermore, there are only limited clinical experience and few published data regarding the safety and efficacy of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> in patients with Child-Pugh class B or more severe cirrhosis [<a href="#rid110">110-113</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The safety and efficacy of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> in patients with liver dysfunction were addressed in an analysis of 1586 patients receiving sorafenib and registered in the international GIDEON study prospective database [<a href="#rid110">110</a>]. The safety profile of sorafenib was similar in patients with Child-Pugh class A and B cirrhosis, but a greater percentage of Child-Pugh class B patients had serious adverse events (60 versus 33 percent), a greater number discontinued therapy due to adverse effects (40 versus 25 percent), and they had a higher rate of deaths during treatment up to 30 days from the last sorafenib dose (37 versus 18 percent).</p><p></p><p class="bulletIndent1">The analysis also highlighted interspecialty differences in treating HCC with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>. In North America, where oncologists prescribe sorafenib, patients often have worse cirrhosis as compared with other areas in the world where hepatologists and gastroenterologists are the prescribers. Despite this variation in treatment practice, toxicity rates (hand-foot syndrome, hematologic toxicities) were similar among all three specialties.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The safety and efficacy of first-line <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> in patients with Child-Pugh class B HCC were addressed in a meta-analysis of 30 studies comprising 8678 patients, 79 percent with Child-Pugh class A cirrhosis and 19 percent with Child-Pugh class B cirrhosis [<a href="#rid113">113</a>]. While the median overall survival (OS) on sorafenib was less for those with Child-Pugh class B cirrhosis (4.6 versus 8.8 months), in contrast to the GIDEON analysis, both groups had similar rates of grade 3 or 4 adverse events during therapy and similar rates of treatment discontinuation without progression.</p><p></p><p>Underlying cirrhosis also makes it more difficult to clear drugs for which there is significant hepatic metabolism, such as <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>. There is controversy as to whether the initial dose of sorafenib needs to be modified in patients with hepatic dysfunction, as evidenced by the following reports:</p><p class="bulletIndent1"><span class="glyph">●</span>The safety of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> in patients with elevated transaminase levels was studied in a subgroup analysis of data from the SHARP trial [<a href="#rid114">114</a>]. Patients with mild or moderate liver dysfunction (≥1.8 times upper limit of normal [ULN]) did not experience increased hepatic or other toxicity. Although median OS was diminished in both placebo-treated and sorafenib-treated patients with moderate liver dysfunction, median TTP and OS favored the sorafenib group regardless of transaminase levels. The authors concluded that treatment was safe and effective, even in patients with mild or moderately elevated baseline transaminase levels, and that hepatic function remained stable over the course of sorafenib therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On the other hand, results from a phase I study suggest that dose reduction to 200 mg twice a day is required in patients with a bilirubin 1.5 to 3 times ULN and that the drug cannot be tolerated with more severe hyperbilirubinemia. (See  <a class="medical medical_review" href="/d/html/128144.html" rel="external">"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Molecularly targeted agents", section on 'Sorafenib'</a>.)</p><p></p><p class="headingAnchor" id="H3747978808"><span class="h3">Dosing considerations</span><span class="headingEndMark"> — </span>Although the manufacturer recommends no <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> dose adjustment for Child-Pugh class B impairment, we recommend reduced-dose therapy (200 mg twice daily, at least initially) in patients with a total bilirubin 1.5 to 3 times the ULN and that the drug not be administered to patients with more severe degrees of hyperbilirubinemia.</p><p>For other patients with Child-Pugh class B cirrhosis, standard dosing from the onset with dose modification as needed is appropriate. However, to improve early tolerability, many clinicians start all patients (regardless of baseline hepatic function) at 200 mg twice a day and increase the daily dose in 200 mg increments approximately every five days, if tolerability is maintained, until the target dose is reached. The available evidence suggests that this approach results in lower rates of adverse events and drug discontinuation, while preserving efficacy [<a href="#rid115">115,116</a>]. Consensus-based guidelines from the National Comprehensive Cancer Network suggest that patients with Child-Pugh class B disease and a total score &gt;7 are not good candidates for <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>  (<a class="graphic graphic_table graphicRef78401" href="/d/graphic/78401.html" rel="external">table 1</a>) [<a href="#rid117">117</a>].</p><p class="headingAnchor" id="H4288750113"><span class="h2">Nivolumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">Nivolumab</a> monotherapy is an alternative to <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> for those with no worse that Child-Pugh B7 cirrhosis who have not undergone liver transplantation. (See <a class="local">'Nivolumab monotherapy'</a> above.)</p><p class="headingAnchor" id="H1386836156"><span class="h2">Systemic chemotherapy</span><span class="headingEndMark"> — </span>For patients who are not candidates for, or intolerant of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, who are not candidates for <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> and who are ineligible for clinical trials or if they are not available, we suggest chemotherapy with GEMOX for fit patients who can tolerate combination chemotherapy. Oral <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> or leucovorin-modulated <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> are options for sick or jaundiced individuals. We choose the regimen based on the level of fitness and hepatic reserve.</p><p>The efficacy of cytotoxic chemotherapy is modest in patients with HCC, and in general, the duration of benefit is limited. No single regimen has emerged as superior to any other, although few randomized trials have been conducted. Despite objective responses that are occasionally complete, median survival in all studies has been short (&lt;12 months in all cases).</p><p>The role of cytotoxic chemotherapy has diminished with the advent of newer immunotherapy and molecularly targeted therapy approaches, which demonstrated better efficacy and tolerability. Cytotoxic chemotherapy has been removed from guidelines for advanced HCC by both the NCCN and ESMO [<a href="#rid3">3,4</a>]. However, at some institutions, chemotherapy is still offered to select patients for third- or fourth-line therapy if they are not optimal candidates for other approved therapies.</p><p>The side effect profile of any chemotherapy regimen should be considered carefully in patients with advanced liver disease and a short life expectancy.</p><p class="headingAnchor" id="H1832411731"><span class="h3">Patients suitable for multiagent chemotherapy</span><span class="headingEndMark"> — </span>Multiple combination cytotoxic regimens have been tested in patients with advanced HCC. Most are of historical interest only. In practice, we most often use GEMOX for patients who are sufficiently fit to tolerate combination chemotherapy.</p><p class="headingAnchor" id="H3498899781"><span class="h4">Gemcitabine based</span></p><p class="bulletIndent1"><span class="glyph">●</span>GEMOX is an active regimen that lacks substantial renal and hepatic toxicity [<a href="#rid118">118-120</a>]. In a phase II study involving 32 cirrhotics with previously untreated advanced HCC (lung metastases in 10, multifocal liver disease in 18, the rest node positive), <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> (1000 mg/m<sup>2</sup> by fixed dose rate infusion) on day 1 was followed by <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> (100 mg/m<sup>2</sup>) on day 2, with both drugs repeated every two weeks [<a href="#rid118">118</a>]. Grade 3 or 4 toxicities included thrombocytopenia (27 percent), neutropenia (24 percent, with two cases of febrile neutropenia), anemia (9 percent), and neuropathy (9 percent). The objective response rate was 18 percent, and an additional 58 percent had disease stabilization. Median survival was 11.5 months. For unclear reasons, treatment seemed to be more effective in patients with nonalcoholic rather than alcoholic cirrhosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another phase II study, the combination of <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> (1250 mg/m<sup>2</sup> on days 1 and 8) and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (70 mg/m<sup>2</sup> on day 1 of every 21-day cycle) was associated with an overall response rate of 20 percent [<a href="#rid121">121</a>]. Grade 3 to 4 toxicities included anemia (37 percent), neutropenia (13 percent), thrombocytopenia (7 percent), transaminitis (3 percent), and mucositis (3 percent). A second trial using a slightly different dosing regimen (cisplatin 25 mg/m<sup>2</sup> on days 1 and 8; gemcitabine 1000 mg/m<sup>2</sup> on days 1 and 8) reported a more favorable toxicity profile but a lower response rate (one partial response among 15 patients) [<a href="#rid122">122</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PLD in combination with <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> is modestly active. In a phase II trial, 41 patients received gemcitabine (1000 mg/m<sup>2</sup> on days 1 and 8) plus PLD (30 mg/m<sup>2</sup> on day 1) every 28 days [<a href="#rid123">123</a>]. There were three complete and seven partial responses (overall response rate 24 percent), median TTP was 5.8 months, and median OS was 22.5 months. Treatment was well tolerated, with grade 3 to 4 toxicity limited to neutropenia (17 percent) and thrombocytopenia (2 percent).</p><p></p><p class="headingAnchor" id="H4086633837"><span class="h4">FOLFOX</span><span class="headingEndMark"> — </span>Regimens containing <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> plus short-term infusional <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> and <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> (FOLFOX) are most commonly used in the treatment of advanced colorectal cancer. (See  <a class="medical medical_review" href="/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'FOLFOX versus FOLFIRI'</a>.)</p><p>Modified FOLFOX 4  (<a class="graphic graphic_table graphicRef64504" href="/d/graphic/64504.html" rel="external">table 8</a>) was directly compared with single-agent <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> (50 mg/m<sup>2</sup> every three weeks) in an Asian trial of 371 patients with advanced or metastatic HCC, 90 percent of whom had HBV infection as the underlying etiology of cirrhosis [<a href="#rid124">124</a>]. Although median progression-free survival (PFS) was significantly better with FOLFOX, it was still quite short (2.93 versus 1.77 months), and there was only a trend toward better median survival (6.4 versus 4.97 months, p = 0.07). FOLFOX was also associated with a higher objective response rate (8 versus 3 percent) and disease control rate (partial response plus stable disease; 52 versus 32 percent). Although the rate of sensory neuropathy was higher in the FOLFOX group (15 versus 0.6 percent), most cases were mild, and there were no significant differences in the rate of grade 3 or 4 toxicities (either hematologic or nonhematologic) between the groups. (See <a class="local">'Doxorubicin and mitoxantrone'</a> below.)</p><p>Interpretation of these results is hampered by the use of a relatively low dose of <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> in the control arm. Furthermore, whether these results can be extrapolated to American patients who have alcohol or HCV, rather than HBV, as the underlying cause of cirrhosis is unclear.</p><p class="headingAnchor" id="H2148923446"><span class="h4">Cisplatin based</span><span class="headingEndMark"> — </span>Cisplatin-based combination regimens appear to result in higher objective response rates (ORRS) than non-cisplatin-containing regimens, although it is not clear that any regimen confers a survival benefit. Response rates with several two- and three-drug regimens are approximately the same:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">Cisplatin</a> plus <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> – Response rate 18 and 49 percent in two studies, one conducted in children (with predominantly HCC rather than the more chemosensitive hepatoblastoma) [<a href="#rid125">125,126</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">Cisplatin</a>, <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a>, and continuous-infusion <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> – Objective response rate 24 and 27 percent in two different studies [<a href="#rid127">127,128</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">Cisplatin</a>, <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a>, and infusional <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> – Response rate 15 percent [<a href="#rid129">129</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">Cisplatin</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> – Response rate 24 percent [<a href="#rid130">130</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sequential low-dose infusional <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> plus infusional <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> – Response rate 43 percent [<a href="#rid131">131</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">Cisplatin</a> plus <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> – Response rate 6 and 20 percent in two studies [<a href="#rid132">132,133</a>].</p><p></p><p>In our view, these cisplatin-based combinations are largely of historic interest only.</p><p class="headingAnchor" id="H2041006330"><span class="h3">Less fit or jaundiced patients</span><span class="headingEndMark"> — </span>For less fit or jaundiced individuals who might not be able to tolerate combination chemotherapy, <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> monotherapy is a reasonable option.</p><p class="headingAnchor" id="H791875431"><span class="h4">Fluoropyrimidines</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">Fluorouracil</a> has acceptably low toxicity and broad antitumor efficacy. Although there is extensive hepatic metabolism, adequate doses can usually be administered in the setting of hepatic dysfunction or jaundice.</p><p>Response rates with <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> monotherapy have been low. However, when given in combination with <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a>, response rates as high as 28 percent have been reported [<a href="#rid134">134</a>], although lower rates have been noted by others [<a href="#rid135">135</a>].</p><p>The benefit of single-agent treatment with the orally active fluoropyrimidine <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> has been addressed in the following reports:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">Capecitabine</a> monotherapy (1000 mg/m<sup>2</sup> twice daily for 14 of every 21 days) was associated with an objective response in 9 of 37 patients (25 percent) in one study, including one complete response [<a href="#rid136">136</a>]. Of the 37 patients, 22 had received no prior therapy for advanced disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Others, using a metronomic <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> schedule (500 mg twice daily every day), also showed better activity for capecitabine monotherapy in patients with previously untreated disease [<a href="#rid137">137</a>]. Among 59 previously untreated patients, there were two complete responses, one partial response, and 30 with stable disease; in a second cohort of 31 patents previously treated with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, there were no objective responses, and stable disease was the best response in 10 patients.</p><p></p><p>However, the superiority of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> over <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> monotherapy as initial therapy was shown in a randomized phase II trial of 52 previously untreated patients with advanced HCC [<a href="#rid138">138</a>]. Both median OS (five versus seven months) and median PFS (four versus six months) were inferior in the capecitabine arm. (See <a class="local">'Sorafenib'</a> above.)</p><p>Nevertheless, for patients who are unable to obtain treatment with molecularly targeted agents, such as <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, fluoropyrimidine monotherapy is an option.</p><p class="headingAnchor" id="H3876487507"><span class="h4">Doxorubicin and mitoxantrone</span><span class="headingEndMark"> — </span>Historically, single-agent <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> has been the most studied chemotherapy agent for advanced HCC. Although an early trial in 1975 reported dramatic clinical activity and a 79 percent response rate, subsequent work suggests that the true objective response rate with doxorubicin monotherapy is 20 percent or less with doses of 75 mg/m<sup>2</sup> [<a href="#rid139">139-145</a>]. Lower doses (≤60 mg/m<sup>2</sup> per cycle) are associated with even lower ORRs [<a href="#rid146">146,147</a>].</p><p>Despite the modest objective response rate, at least two controlled trials, involving 106 and 445 patients, respectively, suggest that <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> is associated with a small survival advantage compared with either best supportive care alone (median survival 10.6 versus 7.5 weeks) [<a href="#rid143">143</a>] or nolatrexed (median survival 32 versus 22 weeks) [<a href="#rid147">147</a>]. The reason for the disparate survival outcomes in these two trials is unclear, but patient selection may have played a role.</p><p>Both <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a> and <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a> have an approximately similar level of antitumor efficacy compared with <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> (response rate 10 to 25 percent) [<a href="#rid148">148-151</a>]. By contrast, the single-agent activity of <a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">pegylated liposomal doxorubicin</a> (PLD) is limited [<a href="#rid152">152-154</a>]. Combination regimens containing PLD are discussed above. (See <a class="local">'Gemcitabine based'</a> above.)</p><p>Anthracyclines require dose modification in patients with liver dysfunction. (See  <a class="medical medical_review" href="/d/html/2837.html" rel="external">"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Conventional cytotoxic agents", section on 'Anthracyclines'</a>.)</p><p class="headingAnchor" id="H2044553479"><span class="h1">CHILD-PUGH CLASS C CIRRHOSIS OR EXTENSIVE COMORBIDITY</span><span class="headingEndMark"> — </span>Supportive care alone is appropriate for patients with Child-Pugh class C cirrhosis  (<a class="graphic graphic_table graphicRef78401" href="/d/graphic/78401.html" rel="external">table 1</a>) and for those with a poor functional status or extensive comorbidity.</p><p>The majority of patients with Child-Pugh class C cirrhosis have liver function that is insufficient to tolerate systemic therapy, and systemic therapy is unlikely to benefit them because of their short survival [<a href="#rid110">110,155</a>]. As an example, in a retrospective report of experience with first-line <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> in 59 patients with HCC (26 with Child-Pugh class A, 23 with Child-Pugh class B, and 10 with Child-Pugh class C cirrhosis), the median survival times in the three groups were 8.3, 4.3, and 1.5 months, respectively [<a href="#rid111">111</a>]. These data support the view that sorafenib is unlikely to benefit patients with Child-Pugh class C cirrhosis.</p><p class="headingAnchor" id="H1809974112"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119333.html" rel="external">"Society guideline links: Hepatocellular carcinoma"</a>.)</p><p class="headingAnchor" id="H25894143"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16838.html" rel="external">"Patient education: Liver cancer (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for systemic therapy</strong> – Systemic therapy is appropriate for patients with advanced unresectable HCC who are unsuitable for locoregional therapy and have adequate performance status and underlying liver function. Clinical trials are preferred whenever available. (See <a class="local">'Indications for systemic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance of assessing hepatic reserve</strong> – HCC is an aggressive tumor often occurring in the setting of chronic liver disease and cirrhosis. Treatment options are influenced by Child-Pugh class  (<a class="graphic graphic_table graphicRef78401" href="/d/graphic/78401.html" rel="external">table 1</a>), a measure of hepatic reserve. (See <a class="local">'General considerations'</a> above.)</p><p></p><p class="bulletIndent1">We limit <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>, <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a>, <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a>, and <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> to those with no worse than Child-Pugh class A cirrhosis, and do not offer <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> to patients with Child-Pugh class B disease and a total score &gt;7. <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">Nivolumab</a> can be administered to patients with Child-Pugh class A or B disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No worse than class A cirrhosis and good functional status</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial therapy</strong> – For patients whose functional status and liver function are adequate (ie, no worse than Child-Pugh class A cirrhosis  (<a class="graphic graphic_table graphicRef78401" href="/d/graphic/78401.html" rel="external">table 1</a>), have no contraindications to <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, and have not recurred following liver transplantation, we suggest <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus bevacizumab rather than other systemic agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Atezolizumab plus bevacizumab'</a> above.)</p><p></p><p class="bulletIndent2">For patients unable to receive <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="139983" href="/d/drug information/139983.html" rel="external">tremelimumab</a> plus <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a> is an alternative to <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus bevacizumab. (See <a class="local">'Tremelimumab plus durvalumab'</a> above.)</p><p></p><p class="bulletIndent2">Immunotherapy should be avoided in patients who recur following liver transplantation because of the high rate of allograft rejection. (See <a class="local">'Checkpoint inhibitor immunotherapy'</a> above.)</p><p></p><p class="bulletIndent2">For patients who are ineligible for or lack access to <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> or <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a> plus <a class="drug drug_general" data-topicid="139983" href="/d/drug information/139983.html" rel="external">tremelimumab</a>, we prefer <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> over <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>. Durvalumab or donafenib (where available) monotherapy are reasonable alternatives to sorafenib in this setting. (See <a class="local">'Lenvatinib'</a> above and <a class="local">'Sorafenib'</a> above and <a class="local">'Durvalumab'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subsequent therapy</strong> – We offer second-line therapy to patients whose tumors progress on first-line therapy or who are unable to tolerate the first-line treatment, and who maintain adequate performance status and preserved liver function. The optimal way to sequence available treatments is not established. We prioritize clinical trials. (See <a class="local">'Second-line therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Treatment of patients who have progressed on <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> or <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a> plus <a class="drug drug_general" data-topicid="139983" href="/d/drug information/139983.html" rel="external">tremelimumab</a> must be individualized as data are limited. Options include <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>, <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a>, <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a>, or apatinib, where available.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For most patients who have progressed on or are unable to tolerate <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> or <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>, we suggest <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef131342" href="/d/graphic/131342.html" rel="external">table 9</a>) rather than other immunotherapy options or a second tyrosine kinase inhibitor (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, this regimen should not be administered to patients with Child-Pugh class B or C. (See <a class="local">'Checkpoint inhibitor immunotherapy'</a> above and <a class="local">'Nivolumab plus ipilimumab'</a> above.)</p><p></p><p class="bulletIndent3"><a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">Pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 6</a>) is an appropriate alternative for those who are unable to tolerate the potential toxicities of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>. (See <a class="local">'Pembrolizumab'</a> above.)</p><p></p><p class="bulletIndent3">Another option following treatment with <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> or <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> is to switch to the other agent or to <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a>. However, whether lenvatinib will work after failure of sorafenib is not known; there are no trials to inform this issue. (See <a class="local">'Lenvatinib'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">Cabozantinib</a> is an option for patients who are intolerant of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>, or <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a>. (See <a class="local">'Cabozantinib'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="94963" href="/d/drug information/94963.html" rel="external">Ramucirumab</a> may be preferred for the subset of patients with a high AFP level (&gt;400 ng/mL). (See <a class="local">'Ramucirumab'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If access to targeted therapies is limited, systemic chemotherapy remains an option for later lines of therapy. Options for fit patients include <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>, gemcitabine plus <a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">pegylated liposomal doxorubicin</a>, or <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> monotherapy. (See <a class="local">'Systemic chemotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Less fit patients or class B cirrhosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For less fit patients who have no worse than Child-Pugh B7 cirrhosis  (<a class="graphic graphic_table graphicRef78401" href="/d/graphic/78401.html" rel="external">table 1</a>), we suggest monotherapy with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> or <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> rather than cytotoxic chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For relatively fit patients with Child-Pugh class B cirrhosis who can tolerate combination chemotherapy and are not candidates for, or intolerant of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> or <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>, and for whom clinical trial participation is not feasible, we suggest chemotherapy with GEMOX rather than an alternative systemic therapy regimen (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Systemic chemotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> or leucovorin-modulated <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> are options for sick or jaundiced individuals. (See <a class="local">'Less fit or jaundiced patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Class C cirrhosis or extensive comorbidity</strong> – Supportive care alone is appropriate for those with Child-Pugh class C cirrhosis, a poor functional status, or extensive comorbidity. (See <a class="local">'Child-Pugh class C cirrhosis or extensive comorbidity'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28:751.</a></li><li><a class="nounderline abstract_t">Nagahama H, Okada S, Okusaka T, et al. Predictive factors for tumor response to systemic chemotherapy in patients with hepatocellular carcinoma. Jpn J Clin Oncol 1997; 27:321.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).</li><li class="breakAll">Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Available online at: https://www.esmo.org/guidelines/gastrointestinal-cancers/hepatocellular-carcinoma/eupdate-hepatocellular-carcinoma-treatment-recommendations (Accessed on May 18, 2022).</li><li><a class="nounderline abstract_t">Griffiths CD, Zhang B, Tywonek K, et al. Toxicity Profiles of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. JAMA Netw Open 2022; 5:e2222721.</a></li><li><a class="nounderline abstract_t">Brar G, Kesselman A, Malhotra A, Shah MA. Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies. JCO Oncol Pract 2022; 18:35.</a></li><li><a class="nounderline abstract_t">Peng Z, Fan W, Zhu B, et al. Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH). J Clin Oncol 2023; 41:117.</a></li><li><a class="nounderline abstract_t">Johnson PJ, Pinato DJ, Kalyuzhnyy A, Toyoda H. Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma. J Clin Oncol 2022; 40:2078.</a></li><li><a class="nounderline abstract_t">Cabibbo G, Enea M, Attanasio M, et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010; 51:1274.</a></li><li><a class="nounderline abstract_t">Huitzil-Melendez FD, Capanu M, O'Reilly EM, et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol 2010; 28:2889.</a></li><li><a class="nounderline abstract_t">Yau T, Yao TJ, Chan P, et al. A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials. Cancer 2008; 113:2742.</a></li><li><a class="nounderline abstract_t">Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29:62.</a></li><li><a class="nounderline abstract_t">Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015; 33:550.</a></li><li><a class="nounderline abstract_t">Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022; 76:681.</a></li><li><a class="nounderline abstract_t">Lee PC, Chao Y, Chen MH, et al. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer 2020; 8.</a></li><li><a class="nounderline abstract_t">Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020; 38:3698.</a></li><li><a class="nounderline abstract_t">Pfister D, Núñez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021; 592:450.</a></li><li><a class="nounderline abstract_t">Spira D, Fenchel M, Lauer UM, et al. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. Acad Radiol 2011; 18:89.</a></li><li><a class="nounderline abstract_t">Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52.</a></li><li><a class="nounderline abstract_t">Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012; 118:147.</a></li><li><a class="nounderline abstract_t">Lencioni R. New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma. Clin Cancer Res 2013; 19:1312.</a></li><li><a class="nounderline abstract_t">Mamdani H, Wu H, O'Neil BH, Sehdev A. Excellent response to Anti-PD-1 therapy in a patient with hepatocellular carcinoma: case report and review of literature. Discov Med 2017; 23:331.</a></li><li><a class="nounderline abstract_t">Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. J Clin Oncol 2020; 38:4317.</a></li><li><a class="nounderline abstract_t">Greten TF, Abou-Alfa GK, Cheng AL, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer 2021; 9.</a></li><li><a class="nounderline abstract_t">Bruix J, Chan SL, Galle PR, et al. Systemic treatment of hepatocellular carcinoma: An EASL position paper. J Hepatol 2021; 75:960.</a></li><li><a class="nounderline abstract_t">Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol 2020; 21:808.</a></li><li><a class="nounderline abstract_t">Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382:1894.</a></li><li><a class="nounderline abstract_t">Galle PR, Finn RS, Qin S, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol 2021; 22:991.</a></li><li><a class="nounderline abstract_t">Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022; 76:862.</a></li><li><a class="nounderline abstract_t">Sonbol MB, Riaz IB, Naqvi SAA, et al. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. JAMA Oncol 2020; 6:e204930.</a></li><li><a class="nounderline abstract_t">Kumar V, Shinagare AB, Rennke HG, et al. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. Oncologist 2020; 25:505.</a></li><li><a class="nounderline abstract_t">Kelley RK, Sangro B, Harris W, et al. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. J Clin Oncol 2021; 39:2991.</a></li><li class="breakAll">Abou-Alfa G, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evidence. Published online 6/6/22. DOI: https://evidence.nejm.org/doi/10.1056/EVIDoa2100070 (Accessed on July 13, 2022).</li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/761289Orig1s001ltr.pdf (Accessed on October 25, 2022).</li><li><a class="nounderline abstract_t">Ikeda K, Kudo M, Kawazoe S, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 2017; 52:512.</a></li><li><a class="nounderline abstract_t">Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018; 391:1163.</a></li><li><a class="nounderline abstract_t">Finn RS, Ikeda M, Zhu AX, et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol 2020; 38:2960.</a></li><li><a class="nounderline abstract_t">Llovet JM, Kudo M, Merle P, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol 2023; 24:1399.</a></li><li><a class="nounderline abstract_t">Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66:11851.</a></li><li><a class="nounderline abstract_t">Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378.</a></li><li><a class="nounderline abstract_t">Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010; 15:85.</a></li><li><a class="nounderline abstract_t">Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25.</a></li><li><a class="nounderline abstract_t">Raoul J, Santoro A, Beaugrand M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: A subanalysis from the SHARP trial. J Clin Oncol 2008; 26S: ASCO #4587.</a></li><li><a class="nounderline abstract_t">Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012; 57:821.</a></li><li><a class="nounderline abstract_t">Jackson R, Psarelli EE, Berhane S, et al. Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials. J Clin Oncol 2017; 35:622.</a></li><li><a class="nounderline abstract_t">Bruix J, Cheng AL, Meinhardt G, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. J Hepatol 2017; 67:999.</a></li><li><a class="nounderline abstract_t">Kolamunnage-Dona R, Berhane S, Potts H, et al. Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. J Hepatol 2021; 75:879.</a></li><li><a class="nounderline abstract_t">Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013; 31:3517.</a></li><li><a class="nounderline abstract_t">Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013; 31:4067.</a></li><li><a class="nounderline abstract_t">Cainap C, Qin S, Huang WT, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 2015; 33:172.</a></li><li><a class="nounderline abstract_t">Reig M, Torres F, Rodriguez-Lope C, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol 2014; 61:318.</a></li><li><a class="nounderline abstract_t">Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol 2013; 36:319.</a></li><li><a class="nounderline abstract_t">Bettinger D, Schultheiss M, Knüppel E, et al. Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma. Hepatology 2012; 56:789.</a></li><li><a class="nounderline abstract_t">Pinter M, Sieghart W, Hucke F, et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011; 34:949.</a></li><li><a class="nounderline abstract_t">Llovet JM, Peña CE, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18:2290.</a></li><li><a class="nounderline abstract_t">Personeni N, Rimassa L, Pressiani T, et al. Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2013; 139:1179.</a></li><li><a class="nounderline abstract_t">Arao T, Ueshima K, Matsumoto K, et al. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology 2013; 57:1407.</a></li><li><a class="nounderline abstract_t">Scartozzi M, Faloppi L, Svegliati Baroni G, et al. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer 2014; 135:1247.</a></li><li><a class="nounderline abstract_t">Ikeda M, Mitsunaga S, Shimizu S, et al. Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. J Gastroenterol 2014; 49:932.</a></li><li><a class="nounderline abstract_t">Gomez-Martin C, Bustamante J, Castroagudin JF, et al. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2012; 18:45.</a></li><li><a class="nounderline abstract_t">Staufer K, Fischer L, Seegers B, et al. High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Transpl Int 2012; 25:1158.</a></li><li><a class="nounderline abstract_t">Kim R, El-Gazzaz G, Tan A, et al. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology 2010; 79:62.</a></li><li><a class="nounderline abstract_t">Zavaglia C, Airoldi A, Mancuso A, et al. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. Eur J Gastroenterol Hepatol 2013; 25:180.</a></li><li><a class="nounderline abstract_t">Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010; 304:2154.</a></li><li><a class="nounderline abstract_t">Abou-Alfa GK, Shi Q, Knox JJ, et al. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. JAMA Oncol 2019; 5:1582.</a></li><li><a class="nounderline abstract_t">Assenat E, Pageaux GP, Thézenas S, et al. Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial. Br J Cancer 2019; 120:896.</a></li><li class="breakAll">Qin S, et al. P-86 Comparison of the Comparison of the pharmacokinetics of donafenib and sorafenib in patients with advanced hepatocellular carcinoma: An open-label, randomized, parallel-controlled, multicentre phase II/III trial (abstract). Abstract available online at https://www.annalsofoncology.org/action/showPdf?pii=S0923-7534%2820%2939467-9 (Accessed on July 01, 2021).</li><li><a class="nounderline abstract_t">Qin S, Bi F, Gu S, et al. Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial. J Clin Oncol 2021; 39:3002.</a></li><li><a class="nounderline abstract_t">Keam SJ, Duggan S. Donafenib: First Approval. Drugs 2021; 81:1915.</a></li><li><a class="nounderline abstract_t">Verset G, Borbath I, Karwal M, et al. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. Clin Cancer Res 2022; 28:2547.</a></li><li><a class="nounderline abstract_t">Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2022; 23:77.</a></li><li><a class="nounderline abstract_t">Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet 2023; 402:1133.</a></li><li class="breakAll">National Medical Products Administration http://english.nmpa.gov.cn/ (Accessed on July 10, 2023).</li><li><a class="nounderline abstract_t">Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol 2021; 22:977.</a></li><li><a class="nounderline abstract_t">Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2022; 23:995.</a></li><li><a class="nounderline abstract_t">Lim H, Ramjeesingh R, Liu D, et al. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review. J Natl Cancer Inst 2021; 113:123.</a></li><li><a class="nounderline abstract_t">Yau T, Kang YK, Kim TY, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol 2020; 6:e204564.</a></li><li class="breakAll">El-Khoueiry AB, Yau T, Kang Y-K, et al. Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040 (abstract). J Clin Oncol 39, 2021 (suppl 3; abstr 269). Abstract available online at https://meetinglibrary.asco.org/record/194242/abstract (Accessed on January 25, 2021).</li><li class="breakAll">YERVOY (ipilimumab) injection, for intravenous use. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125377s108lbl.pdf (Accessed on October 21, 2020).</li><li class="breakAll">FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma . Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-nivolumab-and-ipilimumab-combination-hepatocellular-carcinoma (Accessed on March 12, 2020).</li><li><a class="nounderline abstract_t">Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018; 19:940.</a></li><li><a class="nounderline abstract_t">Kudo M, Finn RS, Edeline J, et al. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. Eur J Cancer 2022; 167:1.</a></li><li><a class="nounderline abstract_t">Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 2020; 38:193.</a></li><li><a class="nounderline abstract_t">Qin S, Chen Z, Fang W, et al. Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 2023; 41:1434.</a></li><li class="breakAll">DailyMed Drug Information: https://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on January 30, 2024).</li><li><a class="nounderline abstract_t">El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017; 389:2492.</a></li><li><a class="nounderline abstract_t">Crocenzi TS, El-Khoueiry AB, Cheung Yau T, et al. Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study. J Clin Oncol 2017; 35S: ASCO #4013.</a></li><li><a class="nounderline abstract_t">Vogel A, Martinelli E, ESMO Guidelines Committee. Electronic address: <span class="__cf_email__" data-cfemail="16757a7f787f75777a71637f72737a7f7873655673657b7938796471">[email protected]</span>, ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol 2021; 32:801.</a></li><li><a class="nounderline abstract_t">Lee DW, Cho EJ, Lee JH, et al. Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. Clin Cancer Res 2021; 27:713.</a></li><li><a class="nounderline abstract_t">Brown ZJ, Heinrich B, Steinberg SM, et al. Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. J Immunother Cancer 2017; 5:93.</a></li><li><a class="nounderline abstract_t">Hodi FS, Ballinger M, Lyons B, et al. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol 2018; 36:850.</a></li><li><a class="nounderline abstract_t">Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389:56.</a></li><li><a class="nounderline abstract_t">Kelley RK, Verslype C, Cohn AL, et al. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol 2017; 28:528.</a></li><li><a class="nounderline abstract_t">Rimassa L, Assenat E, Peck-Radosavljevic M, et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol 2018; 19:682.</a></li><li><a class="nounderline abstract_t">Firtina Karagonlar Z, Koc D, Iscan E, et al. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells. Cancer Sci 2016; 107:407.</a></li><li><a class="nounderline abstract_t">Xiang Q, Chen W, Ren M, et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin Cancer Res 2014; 20:2959.</a></li><li><a class="nounderline abstract_t">Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 2018; 379:54.</a></li><li><a class="nounderline abstract_t">Kelley RK, Meyer T, Rimassa L, et al. Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res 2020; 26:4795.</a></li><li><a class="nounderline abstract_t">Kelley RK, Miksad R, Cicin I, et al. Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade. Br J Cancer 2022; 126:569.</a></li><li><a class="nounderline abstract_t">Zhu AX, Finn RS, Mulcahy M, et al. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res 2013; 19:6614.</a></li><li><a class="nounderline abstract_t">Zhu AX, Park JO, Ryoo BY, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015; 16:859.</a></li><li><a class="nounderline abstract_t">Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20:282.</a></li><li class="breakAll">FDA approves ramucirumab for hepatocellular carcinoma. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ramucirumab-hepatocellular-carcinoma (Accessed on May 13, 2019).</li><li><a class="nounderline abstract_t">Qin S, Li Q, Gu S, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 2021; 6:559.</a></li><li><a class="nounderline abstract_t">Kudo M, Ueshima K, Chan S, et al. Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study. Cancers (Basel) 2019; 11.</a></li><li><a class="nounderline abstract_t">Choi WM, Lee D, Shim JH, et al. Effectiveness and Safety of Nivolumab in Child-Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study. Cancers (Basel) 2020; 12.</a></li><li><a class="nounderline abstract_t">Rimassa L, Personeni N, Czauderna C, et al. Systemic treatment of HCC in special populations. J Hepatol 2021; 74:931.</a></li><li><a class="nounderline abstract_t">Xie E, Yeo YH, Scheiner B, et al. Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. JAMA Oncol 2023; 9:1423.</a></li><li><a class="nounderline abstract_t">D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44:217.</a></li><li><a class="nounderline abstract_t">Lencioni R, Kudo M, Ye SL, et al. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. Int J Clin Pract 2012; 66:675.</a></li><li><a class="nounderline abstract_t">Pinter M, Sieghart W, Graziadei I, et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009; 14:70.</a></li><li><a class="nounderline abstract_t">Abou-Alfa GK, Amadori D, Santoro A, et al. Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. Gastrointest Cancer Res 2011; 4:40.</a></li><li><a class="nounderline abstract_t">McNamara MG, Slagter AE, Nuttall C, et al. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis. Eur J Cancer 2018; 105:1.</a></li><li><a class="nounderline abstract_t">Raoul JL, Bruix J, Greten TF, et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol 2012; 56:1080.</a></li><li><a class="nounderline abstract_t">Reiss KA, Yu S, Mamtani R, et al. Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. J Clin Oncol 2017; 35:3575.</a></li><li><a class="nounderline abstract_t">Kim JE, Ryoo BY, Ryu MH, et al. Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma. Oncology 2012; 82:119.</a></li><li class="breakAll">NCCN Clinical Practice Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx#site (Accessed on June 27, 2019).</li><li><a class="nounderline abstract_t">Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007; 109:1384.</a></li><li><a class="nounderline abstract_t">Mir O, Coriat R, Boudou-Rouquette P, et al. Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib. Med Oncol 2012; 29:2793.</a></li><li><a class="nounderline abstract_t">Zaanan A, Williet N, Hebbar M, et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. J Hepatol 2013; 58:81.</a></li><li><a class="nounderline abstract_t">Parikh PM, Fuloria J, Babu G, et al. A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma. Trop Gastroenterol 2005; 26:115.</a></li><li><a class="nounderline abstract_t">Chia WK, Ong S, Toh HC, et al. Phase II trial of gemcitabine in combination with cisplatin in inoperable or advanced hepatocellular carcinoma. Ann Acad Med Singapore 2008; 37:554.</a></li><li><a class="nounderline abstract_t">Lombardi G, Zustovich F, Farinati F, et al. Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. Cancer 2011; 117:125.</a></li><li><a class="nounderline abstract_t">Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 2013; 31:3501.</a></li><li><a class="nounderline abstract_t">Lee J, Park JO, Kim WS, et al. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol 2004; 54:385.</a></li><li><a class="nounderline abstract_t">Czauderna P, Mackinlay G, Perilongo G, et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 2002; 20:2798.</a></li><li><a class="nounderline abstract_t">Yang TS, Chang HK, Chen JS, et al. Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases. J Gastroenterol 2004; 39:362.</a></li><li><a class="nounderline abstract_t">Ikeda M, Okusaka T, Ueno H, et al. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer 2005; 103:756.</a></li><li><a class="nounderline abstract_t">Boucher E, Corbinais S, Brissot P, et al. Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol 2002; 50:305.</a></li><li><a class="nounderline abstract_t">Park SH, Lee Y, Han SH, et al. Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer 2006; 6:3.</a></li><li><a class="nounderline abstract_t">Kobayashi K, Tsuji A, Morita S, et al. A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma. BMC Cancer 2006; 6:121.</a></li><li><a class="nounderline abstract_t">Shim JH, Park JW, Nam BH, et al. Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 2009; 63:459.</a></li><li><a class="nounderline abstract_t">Lee JO, Lee KW, Oh DY, et al. Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol 2009; 20:1402.</a></li><li><a class="nounderline abstract_t">Porta C, Moroni M, Nastasi G, Arcangeli G. 5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study. Oncology 1995; 52:487.</a></li><li><a class="nounderline abstract_t">Tetef M, Doroshow J, Akman S, et al. 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Cancer Invest 1995; 13:460.</a></li><li><a class="nounderline abstract_t">Patt YZ, Hassan MM, Aguayo A, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004; 101:578.</a></li><li><a class="nounderline abstract_t">Brandi G, de Rosa F, Agostini V, et al. Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study. Oncologist 2013; 18:1256.</a></li><li><a class="nounderline abstract_t">Abdel-Rahman O, Abdel-Wahab M, Shaker M, et al. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol 2013; 30:655.</a></li><li><a class="nounderline abstract_t">Olweny CL, Toya T, Katongole-Mbidde E, et al. Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer 1975; 36:1250.</a></li><li><a class="nounderline abstract_t">Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A, et al. Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep 1984; 68:487.</a></li><li><a class="nounderline abstract_t">Ihde DC, Kane RC, Cohen MH, et al. Adriamycin therapy in American patients with hepatocellular carcinoma. Cancer Treat Rep 1977; 61:1385.</a></li><li><a class="nounderline abstract_t">Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 1988; 15:1.</a></li><li><a class="nounderline abstract_t">Lai CL, Wu PC, Chan GC, et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988; 62:479.</a></li><li><a class="nounderline abstract_t">Choi TK, Lee NW, Wong J. Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. Cancer 1984; 53:401.</a></li><li><a class="nounderline abstract_t">Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97:1532.</a></li><li><a class="nounderline abstract_t">Sciarrino E, Simonetti RG, Le Moli S, Pagliaro L. Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer 1985; 56:2751.</a></li><li><a class="nounderline abstract_t">Gish RG, Porta C, Lazar L, et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 2007; 25:3069.</a></li><li><a class="nounderline abstract_t">Hochster HS, Green MD, Speyer J, et al. 4'Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma. J Clin Oncol 1985; 3:1535.</a></li><li><a class="nounderline abstract_t">Pohl J, Zuna I, Stremmel W, Rudi J. Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma. Chemotherapy 2001; 47:359.</a></li><li><a class="nounderline abstract_t">Colleoni M, Buzzoni R, Bajetta E, et al. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer 1993; 72:3196.</a></li><li><a class="nounderline abstract_t">Dunk AA, Scott SC, Johnson PJ, et al. Mitozantrone as single agent therapy in hepatocellular carcinoma. A phase II study. J Hepatol 1985; 1:395.</a></li><li><a class="nounderline abstract_t">Halm U, Etzrodt G, Schiefke I, et al. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol 2000; 11:113.</a></li><li><a class="nounderline abstract_t">Schmidinger M, Wenzel C, Locker GJ, et al. Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. Br J Cancer 2001; 85:1850.</a></li><li><a class="nounderline abstract_t">Lind PA, Naucler G, Holm A, et al. Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. Acta Oncol 2007; 46:230.</a></li><li><a class="nounderline abstract_t">Giannini EG, Farinati F, Ciccarese F, et al. Prognosis of untreated hepatocellular carcinoma. Hepatology 2015; 61:184.</a></li></ol></div><div id="topicVersionRevision">Topic 2486 Version 124.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9731568" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9390209" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Predictive factors for tumor response to systemic chemotherapy in patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9390209" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Predictive factors for tumor response to systemic chemotherapy in patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9390209" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Predictive factors for tumor response to systemic chemotherapy in patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35849393" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Toxicity Profiles of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34255552" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35921605" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35344390" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20112254" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20458042" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Advanced hepatocellular carcinoma: which staging systems best predict prognosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18853421" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9862851" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25512453" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34801630" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32863270" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32716741" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33762733" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : NASH limits anti-tumour surveillance in immunotherapy-treated HCC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20926315" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20175033" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21713764" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23382112" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28715649" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Excellent response to Anti-PD-1 therapy in a patient with hepatocellular carcinoma: case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33197225" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34518290" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34256065" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Systemic treatment of hepatocellular carcinoma: An EASL position paper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32502443" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32402160" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34051880" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34902530" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33090186" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32043699" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292792" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292792" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292792" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27704266" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29433850" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32716739" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38039993" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17178882" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18650514" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Sorafenib in advanced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20051477" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19095497" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: A subanalysis from the SHARP trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22727733" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28045619" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28687477" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34052255" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23980084" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24081937" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25488963" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24703956" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22547010" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22307848" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21883324" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22374331" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23568548" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22890726" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24510746" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23793266" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21932373" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22882364" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21071991" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23044808" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21081728" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31486832" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30944458" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30944458" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34185551" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34591285" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Donafenib: First Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35421228" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34914889" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37499670" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37499670" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34143971" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35798016" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32898239" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33001135" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33001135" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33001135" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33001135" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29875066" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35364421" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31790344" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36455168" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36455168" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28434648" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33716105" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33139266" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29157287" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29341833" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27932229" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28426123" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29625879" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26790028" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24700742" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29972759" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32636319" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34621044" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24088738" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26095784" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30665869" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increasedα-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30665869" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increasedα-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33971141" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31370183" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32698355" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Effectiveness and Safety of Nivolumab in Child-Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33248171" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Systemic treatment of HCC in special populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37615958" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16298014" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22698419" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19144684" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21673874" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30384012" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22245896" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28872925" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22354124" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22354124" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17330837" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22427209" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22989572" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16512457" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18695766" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Phase II trial of gemcitabine in combination with cisplatin in inoperable or advanced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21058409" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23980077" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15248028" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12065556" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15168248" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15637692" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12357305" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16396674" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16677397" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18437384" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19502532" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7478436" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : 5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7552810" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15274071" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24232581" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23824645" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/169983" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6322986" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/201380" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Adriamycin therapy in American patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2834053" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Clinical trials in primary hepatocellular carcinoma: current status and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2839280" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6198058" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16234567" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2413981" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634485" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2997408" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : 4'Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11561139" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8242542" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2997322" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Mitozantrone as single agent therapy in hepatocellular carcinoma. A phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10690399" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11747325" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17453374" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25234419" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Prognosis of untreated hepatocellular carcinoma.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
